

**CURRICULUM VITAE
OF
PROF. DR. J.H.G. JONKMAN**

TABLE OF CONTENTS

	<u>PAGE:</u>
1. CURRICULUM VITAE.....	3
2. PUBLICATIONS.....	12
3. BOOKS	44
4. LECTURES.....	45

1. CURRICULUM VITAE

PROF. DR. J.H.G. JONKMAN

SURNAME

Jonkman

CHRISTIAN NAME(S)

Jan Hasker Gerhardus

NATIONALITY

Dutch

SEX

Male

DATE OF BIRTH

February 15, 1946

PLACE OF BIRTH

Oosterwolde, The Netherlands

EDUCATION

- 1958-1963 : Secondary School (Dutch system: HBS-B), Oosterwolde
Graduation June 21, 1963
- 1963-1971 : University of Groningen, The Netherlands, School of Pharmacy
Pharmacist certification (R.Ph.) July 08, 1971
- 1971-1977 : Research for Ph.D.-thesis: 'Thiazinamium methylsulphate, bioanalysis and
pharmacokinetics'
Promotores: Prof. Dr. J.S. Faber, Dr. R.A. de Zeeuw, University of
Groningen
Ph.D. June 20, 1977

PRACTICAL TRAINING

- 1972 : Training in pharmacokinetics, Chelsea College
(Prof. Dr. A.H. Becket), London, UK
- 1974 : Training in ion pair extraction at the Laboratory for
Pharmaceutical-Analytical Chemistry, University of Uppsala
(Prof. Dr. G. Schill), Uppsala, Sweden
- 1975-1976 : Training in autoradiography and pharmacokinetics at the
University of Nijmegen (Dr. E. van der Kleijn), The Netherlands.
Performed autoradiographic studies with promethazine,
thiazinamium (= N-methylpromethazine) and carbamazepine

SUMMARY OF RELEVANT EXPERIENCE

Originally trained as a bioanalytical scientist Prof. Dr. Jonkman gained extensive knowledge and experience over the years in clinical pharmacology (especially pharmacokinetics/dynamics and –genetics). He performed/supervised over 1,000 Phase I studies and 1,250 bioanalytical projects. He was an author or co-author of over 290 publications and gave over 220 lectures on national and international conferences. More recently he specialised in all aspects of quality management of drug research.

PROFESSIONAL EXPERIENCE

- 1965-1971 : Student-assistant in physiology and analytical chemistry
- 1971-1977 : Senior Research Scientist, University of Groningen
Development of several new bioanalytical assays for quaternary ammonium compounds (drugs and metabolites).
Clinical pharmacokinetic studies on thiazinamium methylsulphate (Multergan⁷), a quaternary ammonium compound (anticholinergic) used as bronchodilator in patients suffering from generalized chronic obstructive lung disease. These studies were performed together with Dr. L.E. van Bork (specialist in lung diseases) at the Pulmonary Division of the

- Department of Internal Medicine (Director: Prof. Dr. N.G.M. Orie),
University of Groningen.
A number of studies on bioanalysis, biopharmaceutics and clinical pharmacokinetics of theophylline, University of Groningen
- 1977-1984 : Owner/director of 'Karsten Pharmacy', Assen, The Netherlands
 - 1977-1991 : On a part-time basis, senior research scientist at the School of Pharmacy, University of Groningen
 - 1979-1981 : 'International Visiting Scientist' at the University of California, San Francisco, USA, School of Pharmacy, Department of Pharmacy (Prof. Dr. S. Riegelman); bioanalysis and pharmacokinetics.
Developed a selective assay for simultaneous determination of theophylline and its major metabolites 3-methylxanthine, 1-methyluric acid and 1,3-dimethyluric acid in urine
 - 1982-1983 : Training in biopharmaceutics, Food and Drug Administration, Biopharmaceutics Laboratory (U.S. Government), Washington D.C., USA (Dr. V.K. Prasad and Dr. B.E. Cabana).
'International Visiting Scientist' for scientific consultancy by Food and Drug Administration, Biopharmaceutics Laboratory (U.S. Government), Washington D.C. (Dr. V.K. Prasad and Dr. J.P. Skelly), and training in registration procedures
 - 1984-1999 : President (Founder/Owner) & CEO and Executive Director Scientific Affairs of Pharma Bio-Research International B.V. in Zuidlaren/Assen, The Netherlands. Pharma Bio-Research is an independent contract research organization and was founded by Dr. J.H.G. Jonkman in 1984. At present this organization comprises an institute for pharmaceutical and biomedical consultancy, an institute for clinical pharmacology and laboratories for pharmaceutical analysis, bioanalysis and clinical chemistry (appr. 300 employees in 1999)
 - 1996-2018 : Professor Quality Management in Drug Research and Manufacturing, School of Pharmacy, University of Groningen
 - 2000-2003 : Senior Director Institute of Clinical Pharmacology
PAREXEL GmbH, Berlin, Germany
 - 2000-2003 : Vice President Scientific Relations Clinical Pharmacology International
PAREXEL GmbH, Berlin, Germany
 - 2005-date : President/owner PharmAdvices Drug Development Consultancy Company, Zuidwolde, The Netherlands

COURSES

- 1987 : Course PC-DOS/MS-DOS, Randstad Opleidingscentrum, Zwolle, The Netherlands

- 1991 : Boerhaave course 'Medicamenteuze therapie in 2000', University of Leiden, The Netherlands
- 1992 : Course on clinical pharmacology, University Hospital Groningen, The Netherlands
- 1993 : Course on Good Clinical Practices (International Standards and Quality Assurance), Zeegse, The Netherlands (given by Good Clinical Research Practices Ltd., Dr. W.P. Bohaychuk and Dr. G.J. Ball)
- 1994 : Course on Good Laboratory Practices (International Standards and Quality Assurance), Zeegse, The Netherlands (given by The Center for Professional Advancement/Goldman Associates International Inc., Dr. S. Gordon and Dr. D.S. Goldman)

RESEARCH INTERESTS

- total quality management in pharmaceutical and biomedical research and medicine production (Good Clinical Practice, Good Laboratory Practice and Good Manufacturing Practice)
- drug assay development
- biopharmaceutics (in particular of sustained release dosage forms)
- bioequivalence studies (several drugs)
- chronopharmacology (especially chronopharmacokinetics)
- drug-drug interactions
- food-drug interactions
- genomics and polymorphism in drug metabolism
- first administration of New Chemical Entities to humans

MEMBERSHIPS

- Koninklijke Nederlandse Maatschappij ter Bevordering der Pharmacie (Royal Dutch Association for Advancement of Pharmacy)
- Koninklijke Nederlandse Chemische Vereniging, Sectie Farmacochemie (Royal Dutch Chemical Society, Section Medicinal Chemistry)
- Koninklijke Nederlandse Chemische Vereniging, Sectie Analytische Chemie (Royal Dutch Chemical Society, Section Analytical Chemistry)
- Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie (Dutch Society for Clinical Pharmacology and Biopharmaceutics)
- Vereniging Nederlandse Industrie-Apothekers (Dutch Association of Industrial Pharmacists)
- Nederlandse Vereniging van Ziekenhuis-Apothekers (Dutch Association of Hospital Pharmacists)
- Nederlandse Vereniging voor Toxicologie (Dutch Association for Toxicology)
- Nederlandse Vereniging voor Farmaceutische Wetenschappen (Dutch Association for Pharmaceutical Sciences)
- Nederlandse Vereniging van Farmaceutische Geneeskundigen (NVFG: Dutch Association for Pharmaceutical Physicians)
- Nederlands Centrum van Directeuren en Commissarissen (Dutch Centre of Directors and Members of the Board of Commissioners)
- Dutch Association of Research Quality Assurance (DARQA)
- British Association of Research Quality Assurance (BARQA)
- British Pharmacological Society (+ Section Clinical Pharmacology)
- The Royal Society of Medicine

- International Union of Pharmacology (IUPHAR), Section Clinical Pharmacology
- Academy of Pharmaceutical Research and Science
- American Association of Pharmaceutical Scientists
- American Chemical Society (Division of Analytical Chemistry)
- American College of Clinical Pharmacology
- American Society for Clinical Pharmacology and Therapeutics
- Association for Clinical Research
- Association of Official Analytical Chemists
- Drug Information Association
- Fédération Internationale Pharmaceutique (International Pharmaceutical Federation)
- Gesellschaft für Klinische Pharmakologie e.V. (Association for Clinical Pharmacology)
- Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V. (International Association for Pharmaceutical Technology)
- Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie (German Association for experimental and clinical Pharmacology and Toxicology)
- Deutsche Gesellschaft für Pharmazeutische Medizin e.V. (DG PharMed; German Association for Pharmaceutical Medicine)
- European Federation for Pharmaceutical Sciences
- European Forum for Good Clinical Practice
- Association of Clinical Research Professionals

COMMITTEES

- member of the Management-Committee of COST- B15 Project “Modelling During Drug Development”, Commission of the European Community (Brussels)
- member of former Management-Committee of COST-B1 Project ‘The Role of Metabolic and Kinetic Studies in Drug Research and Development’, Commission of the European Community (Brussels)
- former member of the Executive Committee of the Association of Independent Clinical Research Contractors (AICRC)
- former member of the Board of the European Forum for Good Clinical Practice (Brussels)
- former member of the ‘Committee for Pharmaceutical and Biomedical Analysis’ of the Koninklijke Nederlandse Chemische Vereniging (Royal Dutch Chemical Society)
- former member of the working group ‘Quality Assurance in Pharmaceutical Analysis’
- former member of the ‘Committee on Doping’ (expert on bioanalysis; National Institute for Sport and Health)
- former member (chairman) of the ‘Laboratory Committee’ of the Koninklijke Nederlandse Maatschappij ter Bevordering der Pharmacie (Royal Dutch Association for Advancement of Pharmacy)
- former member of the ‘Committee for National Monographies’ (The Dutch Pharmacopoeia Commission)
- former member of the Board of the ‘Centre for Innovation Drenthe’ (Innovatie Centrum Drenthe)

SPECIAL APPOINTMENTS/AWARDS

- appointed as ‘Expert Pharmacology/Toxicology’ by the French Government on July 08, 1983 (Appointment published in ‘Bulletin Officiel du Ministère des Affaires Sociales et de la Solidarité Nationale’ no. 31, September 02, 1983)
- appointed as ‘Expert Analyse’ by the French Government on June 03, 1987
- appointed as ‘Biomedical Scientist/Toxicologist’ by the ‘Stichting voor Opleiding tot Medisch Biologisch Wetenschappelijk Onderzoeker’ (Society for Training of Medical Biological Scientific Researcher), The Netherlands, March 18, 1988
- acknowledged as ‘Fellow’ of the American College of Clinical Pharmacology, June 09, 1989
- appointed as Scientific Adviser of the Groningen Institute for Drug Studies, University of Groningen, 1993

- acknowledged as honorary member of 'Pharmaciae Sacrum', the association of pharmacy students at the University of Groningen on October 13, 1992
- appointed as 'Referee' for the Ph.D.-thesis of Dr. J. Wieling entitled: 'Liquid-liquid extractions of drugs from biological fluids: robotization and optimization', May 03, 1993, University of Groningen
- appointed as honorary member ('Fellow') of the Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie (Dutch Society for Clinical Pharmacology and Biopharmaceutics), 1993
- King William I Award 1993. This plaque is awarded biannually to a company which has contributed in an exceptional degree to the economic activity of The Netherlands as a source of employment and welfare, and which not only conducts its affairs in accordance with the requirements of sound business management, but also has distinguished itself by outstanding achievements in a specific area. The prestigious plaque was presented to Dr. J.H.G. Jonkman on June 01, 1993, by his Royal Highness Prince Claus of The Netherlands in the 'Ridderzaal' in The Hague, The Netherlands
- appointed as honorary member ('Fellow') of the American Association of Pharmaceutical Scientists (AAPS), 1995
- elected as 'Entrepreneur of the year 1995 - Drenthe'
- awarded with the '1998 Wubbo Ockels Award of the City of Groningen'. The prize is awarded biannually (for the first time to Prof. W.J. Ockels in 1985) for an extraordinary achievement in the field of natural science or technology. Prof. J.H.G. Jonkman was awarded the prize for 'his significant contribution to the professionalization of scientific research aimed at the development of new drugs', according to the jury's report. The 1998 Wubbo Ockels Award was presented by Mr. J. Wallage, Mayor of the city of Groningen. The title of Prof. Jonkman's speech of thanks was: Pharmacogenetic aspects of drug development and pharmacotherapy ('on genotyping and phenotyping').
- Appointed as honorary member ("Fellow") of the Research Quality Association (United Kingdom), 2010.

REFEREESHIP

- acts frequently as a referee for several scientific journals such as Pharmaceutical Research, Journal of Pharmaceutical Sciences, Clinical Pharmacokinetics, Journal of Chromatography B-Biomedical Applications, European Respiratory Journal, British Journal of Clinical Pharmacology, Biopharmaceutics and Drug Disposition, European Journal of Epidemiology, Pharmacology and Toxicology, and Pharmacy World & Science (Pharmaceutisch Weekblad, Scientific Edition)

PUBLICATIONS

- author (or co-author) of over 290 scientific articles (research papers, reviews and abstracts); including the papers of co-workers to which he contributed without being mentioned as author

LECTURES

- has given over 185 lectures at (inter)national conferences and courses

2. PUBLICATIONS

1974

1. J.H.G. Jonkman.
Kwantitatieve analyse van thiazinamium methylsulfaat (Multergan®) in lichaamsvloeistoffen.
Pharm. Weekbl. 109(1974)1095-1099.
2. J.H.G. Jonkman, J. Wijsbeek, S. Hollenbeek Brouwer-de Boer and R.A. de Zeeuw.
Bioavailability of the quaternary ammonium compound thiazinamium methylsulphate (Multergan®) after oral and intramuscular administration.
J. Pharm. Pharmacol. 26(1974)63P.

1975

3. R.A. de Zeeuw, J.H.G. Jonkman and F.J. van Mansvelt.
Plasticizers as contaminants in high-purity solvents; A potential source of interference in biological analysis.
Anal. Biochem. 67(1975)339-341.
4. J.H.G. Jonkman.
Ionpaar-extractie als isoleringsmethode bij de analyse van geneesmiddelen en metabolieten in lichaamsvloeistoffen; I. Inleiding en algemene principes.
Pharm. Weekbl. 110(1975)649-655.
5. J.H.G. Jonkman.
Ionpaar-extractie als isoleringsmethode bij de analyse van geneesmiddelen en metabolieten in lichaamsvloeistoffen; II. Praktische uitvoering en toepassingen.
Pharm. Weekbl. 110(1975)673-689.
6. J.H.G. Jonkman, J. Wijsbeek, S. Hollenbeek Brouwer-de Boer, R.A. de Zeeuw, L.E. van Bork and N.G.M. Orie.
Determination of low concentrations of the quaternary ammonium compound thiazinamium methylsulphate in plasma and urine.
J. Pharm. Pharmacol. 27(1975)849-854.
7. L.E. van Bork, J.H.G. Jonkman, N.G.M. Orie and R.A. de Zeeuw.
Thiazinamium methylsulphate; a drug with anticholinergic and antihistaminic properties: its use in chronic generalized obstructive lung disease.
Tubercle 56(1975)244.

1976

8. J.H.G. Jonkman, R.A. de Zeeuw, L.E. van Bork and N.G.M. Orie.
Bioavailability after intramuscular injection.
Lancet i(1976)693.

9. J.H.G. Jonkman, J. Wijsbeek, J.E. Greving, R.E. van Gorp and R.A. de Zeeuw.
Determination of thiazinamium sulphoxide in urine by means of Amberlite XAD-2 column chromatography and thin-layer densitometry.
J. Chromatog. 128(1976)208-211.
10. J.H.G. Jonkman, L.E. van Bork, J. Wijsbeek, R.A. de Zeeuw en N.G.M. Orie.
De biologische beschikbaarheid van de kwaternaire ammonium verbinding thiazinamium methylsulfaat (Multergan®) na verschillende wijzen van toediening bij de mens.
Pharm. Weekbl. 111(1976)1209-1216.
11. J.H.G. Jonkman, L.E. van Bork, J. Wijsbeek, R.A. de Zeeuw, N.G.M. Orie and H.L.M. Cox.
First pass effect after rectal administration of thiazinamium methylsulphate.
J. Pharm. Pharmacol. 28(1976)56P.

1977

12. J.H.G. Jonkman, L.E. van Bork, J. Wijsbeek, R.A. de Zeeuw and N.G.M. Orie.
Variations in the bioavailability of thiazinamium methylsulfate.
Clin. Pharmacol. Ther. 21(1977)457-463.
13. J.H.G. Jonkman, H.G.M. Westenberg and E. van der Kleijn.
A comparison of the distribution of promethazine and its quaternary analogue in mice and monkey.
Acta Pharmacol. Toxicol. 41(1977)Suppl. 1, 124-125.
14. E. van der Kleijn, N.V.M. Rijntjes, T.B. Vree, F. Schobben, H.G.M. Westenberg, J.H.G. Jonkman, H.J. Knop and H. van Geyn.
Similarities and differences in the kinetics of distribution and placental transfer of antiepileptic drugs of extremely varying physico-chemical properties.
Acta Pharmacol. Toxicol. 41(1977)Suppl. 1, 168-169.
15. H.G.M. Westenberg, J.H.G. Jonkman and E. van der Kleijn.
The distribution of carbamazepine and its metabolite in squirrel monkey and mouse.
Acta Pharmacol. Toxicol. 41(1977)Suppl. 1, 136-137.
16. L.E. van Bork, J.H.G. Jonkman, R.A. de Zeeuw, N.G.M. Orie, R. Peset and K. de Vries.
Diagnostisch en therapeutisch gebruik van thiazinamium methylsulfaat (Multergan®).
Ned. T. v. Geneesk. 121(1977)1196-1202.
17. J.E. Greving, J.H.G. Jonkman, F. Fiks, R.A. de Zeeuw, L.E. van Bork and N.G.M. Orie.
Determination of oxyphenonium bromide in plasma and urine by means of ion-pair extraction, derivatization and gas chromatography.
J. Chromatog. 142(1977)611-619.
18. J.H.G. Jonkman.
Thiazinamium methylsulphate, Bioanalysis and Pharmacokinetics.
Ph.D. Thesis, University of Groningen (1977).

1978

19. J.E. Greving, J.H.G. Jonkman and R.A. de Zeeuw.
Determination of carboxylic acids in the picomole range after derivatization with pentafluorobenzyl bromide and electron capture detection gas chromatography.
J. Chromatog. 148(1978)389-395.
20. K. Neef, J.H.G. Jonkman and D.K.F. Meijer.
Hepatic disposition and biliary excretion of the organic cations thiazinamium and thiazinamium sulfoxide in rats.
J. Pharm. Sci. 67(1978)1147-1149.

1979

21. J.H.G. Jonkman, L.E. van Bork, J. Wijsbeek, A.S. Bolhuis-de Vries, R.A. de Zeeuw, N.G.M. Orie and H.L.M. Cox.
First-pass effect after rectal administration of thiazinamium methylsulfate.
J. Pharm. Sci. 68(1979)69-71.
22. J.H.G. Jonkman, L.E. van Bork, J. Wijsbeek, A.S. Bolhuis-de Vries, R.A. de Zeeuw, N.G.M. Orie and H.L.M. Cox.
Bioavailability after rectal administration of thiazinamium methylsulphate in different vehicula.
Int. J. Pharm. 3(1979)55-64.
23. J.H.G. Jonkman.
Enkele aspecten van behandeling en medicatie bij CARA.
Pharm. Weekbl. 114(1979)629-648.
24. J.H.G. Jonkman.
Een klinisch farmacokinetische vergelijking van orale en rectale toediening van thiazinamium methylsulfaat.
Pharm. Weekbl. 114(1979)997-1001.
25. J.H.G. Jonkman, L.E. van Bork, J. Wijsbeek, A.S. Bolhuis-de Vries, R.A. de Zeeuw, J.E. Greving and N.G.M. Orie.
Disposition of thiazinamium in humans after administration as an ion pair; I. Oral administration.
Pharm. Weekbl. Sci. Ed. 1(1979)121-124.
26. J.H.G. Jonkman, L.E. van Bork, J. Wijsbeek, A.S. Bolhuis-de Vries, R.A. de Zeeuw, J.E. Greving, N.G.M. Orie and H.L.M. Cox.
Disposition of thiazinamium in humans after administration as an ion pair; II. Rectal administration.
Pharm. Weekbl. Sci. Ed. 1(1979)124-128.
27. J.H.G. Jonkman, W.Chr. Berg, R. Schoenmaker, J.E. Greving, R.A. de Zeeuw and N.G.M. Orie.
The absolute bioavailability of microcrystalline theophylline.
Current Medical Research and Opinion, Vol. 6(1979)Suppl. 6, 71-76.

28. W.Chr. Berg, J.H.G. Jonkman, K. de Vries and N.G.M. Orie.
A multi-dose comparative study of microcrystalline theophylline and a choline theophyllinate.
Current Medical Research and Opinion, Vol. 6(1979)Suppl. 6, 64-70.
29. J.E. Greving, H. Bouman, J.H.G. Jonkman, H.G.M. Westenberg and R.A. de Zeeuw.
Analysis of quaternary ammonium compounds and basic drugs based on ion-pair absorption high-performance liquid chromatography.
J. Chromatog. 186(1979)683-690.

1980

30. A.M. Soeterboek and J.H.G. Jonkman.
'Clinical pharmacokinetic aspects of theophylline', in: 'The Serum Concentration of Drugs'
(F.W.H.M. Merkus, Ed.),
Excerpta Medica, Amsterdam (1980)250-259.
31. J.E. Greving, J.H.G. Jonkman, H.G.M. Westenberg and R.A. de Zeeuw.
Novel chromatographic methods for monitoring quaternary ammonium compounds in biological fluids.
Pharm. Weekbl. Sci. Ed. 2(1980)81-87.
32. J.H.G. Jonkman, R. Schoenmaker, J.E. Greving and R.A. de Zeeuw.
Rapid and selective theophylline serum and saliva assay by means of high pressure liquid chromatography.
Pharm. Weekbl. Sci. Ed. 2(1980)49-53.
33. J.H.G. Jonkman, W.Chr. Berg, R. Schoenmaker, J.E. Greving, R.A. de Zeeuw and N.G.M. Orie.
Disposition and clinical pharmacokinetics of microcrystalline theophylline.
Eur. J. Clin. Pharmacol. 17(1980)379-384.
34. K.T. Muir, J.H.G. Jonkman, D.S. Tang, M. Kunitani and S. Riegelman.
Simultaneous determination of theophylline and its major metabolites in urine by reversed-phase ion pair high-performance liquid chromatography.
J. Chromatog. Biom. Appl. 221(1980)85-95.
- 34A. J.H.G. Jonkman.
Middelen voor gebruik bij astma, bronchitis en slappe long (CARA).
Geneesmiddelen in Nederland; Gids voor arts en gebruiker (L. Reijnders, H. Buurma, A. Vulto e.a., Eds), Van Gennep, Amsterdam (1980)270-281.

1981

35. J.H.G. Jonkman, H.G.M. Westenberg and E. van der Kleijn.
Hepatic first pass effect of thiazinamium methylsulfate (N-methylpromethazine).
J. Pharm. Sci. 70(1981)947-949.
36. J.H.G. Jonkman, M.B. Holtkamp-Zieleman, E.M. Hoff-v.d. Berg, N. Grimberg en R. Schoenmaker.
Oploskarakteristieken van enkele choline theofyllinaat tabletten.
Pharm. Weekbl. 116(1981)665-671.

37. J.H.G. Jonkman, R. Schoenmaker, N. Grimberg and R.A. de Zeeuw.
A new in vitro dissolution test for controlled-release theophylline tablets.
Int. J. Pharm. 8(1981)153-156.
38. J.H.G. Jonkman, W.Chr. Berg, G.H. Koëter, N. Grimberg, R. Schoenmaker, R.A. de Zeeuw and K. de Vries.
'The correlation between 'in vitro' dissolution and 'in vivo' disposition of sustained release theophylline tablets', in 'Proceedings of the First European Congress of Biopharmaceutics and Pharmacokinetics' (J.M. Aiache and J. Hirtz, Eds.), Technique et Documentation, Paris, Vol. 1(1981)182-191.
39. J.H.G. Jonkman, G.H. Koëter, R. Schoenmaker, K. de Vries, J.E. Greving and R.A. de Zeeuw.
Correlation of serum and saliva theophylline concentrations after administration of a sustained release preparation.
Eur. J. Clin. Pharmacol. 20(1981)73-78.
40. J.H.G. Jonkman, D.S. Tang, R.A. Upton and S. Riegelman.
Measurement of excretion characteristics of theophylline and its major metabolites.
Eur. J. Clin. Pharmacol. 20(1981)435-441.
41. J.H.G. Jonkman, W.Chr. Berg, K. de Vries, R.A. de Zeeuw, R. Schoenmaker and N. Grimberg.
Disposition and clinical pharmacokinetics of theophylline after administration of a new sustained-release tablet.
Eur. J. Clin. Pharmacol. 21(1981)39-44.
42. G.H. Koëter, J.H.G. Jonkman, K. de Vries, R. Schoenmaker, J.E. Greving and R.A. de Zeeuw.
Pharmacokinetics of sustained release theophylline at low and high multidose regimen.
Br. J. Clin. Pharmac. 12(1981)647-651.
43. P.A.G.M. de Smet en J.H.G. Jonkman.
Gebruik en dosering van aminofylline zetpillen.
Pharm. Weekbl. 116(1981)1526-1530.
44. P.A.G.M. de Smet en J.H.G. Jonkman.
Gebruik en dosering van aminofylline zetpillen.
Ned. T. v. Geneesk. 125(1981)2059-2063.
45. J.H.G. Jonkman, J.P. Franke, R. Schoenmaker and R.A. de Zeeuw.
Stability of theophylline in serum, plasma and saliva stored at different temperatures.
Clin. Chem. 27(1981)2071-2072.
- 45A. J.H.G. Jonkman en G.H. Koëter.
Dodelijke theofylline-intoxicaties na foutieve intraveneuze dosering.
Ned. T. Geneesk. 125(1981)23-24.

1982

46. P.A.G.M. de Smet, J.J. Grote en J.H.G. Jonkman.
Praktische eerste aanpak van pseudokroep.
Pharm. Weekbl. 117(1982)39-41.
47. P.A.G.M. de Smet, J.J. Grote en J.H.G. Jonkman.
Praktische eerste aanpak van pseudokroep.
Ned. T. v. Geneesk. 126(1982)63-65.
48. J.H.G. Jonkman, J.P. Franke, R. Schoenmaker and R.A. de Zeeuw.
Influence of sample preparation and storage on theophylline concentrations in biological fluids.
Int. J. Pharm. 10(1982)177-180.
49. J.H.G. Jonkman, W.Chr. Berg and R. Schoenmaker.
'Nonreproducible serum concentration-time profiles after intake of a new sustained release theophylline tablet', in 'Methods in Clinical Pharmacology', No. 3, 'Theophylline and other methylxanthines' (N. Rietbrock and B.G. Woodcock, Eds.), F. Vieweg & Sohn, Braunschweig/Wiesbaden (1982)39-45.
50. J.H.G. Jonkman, K.T. Muir, D.S. Tang and S. Riegelman.
'Selective quantitative determination of methylxanthines and methyluric acids in urine', in 'Methods in Clinical Pharmacology', No. 3, 'Theophylline and other methylxanthines' (N. Rietbrock and B.G. Woodcock, Eds.), F. Vieweg & Sohn, Braunschweig/Wiesbaden (1982)169-174.
51. G.H. Koëter, R.A. de Zeeuw, J.H.G. Jonkman, J.E. Greving, L.E. van Bork, H. Meurs, H.J. Sluiter en K. de Vries.
'Bronchusverwijdende therapie bij CARA', in 'Voordrachten gehouden in het kader van de 10^e Groninger Internistencursus' (S.J. Horntje en P.E. de Jong, Eds.), Groningen (1982)77-82.
52. J.H.G. Jonkman, R.A. de Zeeuw and R. Schoenmaker.
Interference with proposed selected method for theophylline HPLC-assay.
Clin. Chem. 28(1982)1987-1988.
53. J.H.G. Jonkman, J. Wijsbeek, R.A. de Zeeuw, L.E. van Bork, N.G.M. Orie, A.M. Soeterboek and J. Bender.
Metabolism and excretion of the quaternary ammonium compound thiazinamium methylsulphate (Multergan[®]) in man. I. Parenteral administration.
Pharm. Weekbl. Sci. Ed. 4(1982)122-128.
54. J.H.G. Jonkman, J. Wijsbeek, R.A. de Zeeuw, L.E. van Bork and N.G.M. Orie.
Metabolism and excretion of the quaternary ammonium compound thiazinamium methylsulphate (Multergan[®]) in man. II. Oral and rectal administration.
Pharm. Weekbl. Sci. Ed. 4(1982)129-134.

55. L.E. van Bork, J.H.G. Jonkman, J.E. Greving, N.G.M. Orië, R. Peset, K. de Vries and R.A. de Zeeuw.
Pharmacodynamics of thiazinamium methylsulphate and oxyphenonium bromide and the difference in effect between aerosol of oxyphenonium bromide or ipratropium bromide and a metered aerosol of oxyphenonium bromide.
Bull. Eur. Physiopath. Resp. 18(1982)77P.
56. J.E. Greving, J.H.G. Jonkman, L.E. van Bork, N.G.M. Orië and R.A. de Zeeuw.
Pharmacokinetics of thiazinamium methylsulphate and oxyphenonium bromide in relation to its pharmacodynamics.
Bull. Eur. Physiopath. Resp. 18(1982)76P.

1983

57. M.Lagas and J.H.G. Jonkman.
Influence of food on the bioavailability of theophylline when administered as a new sustained release tablet.
Pharm. Weekbl. Sci. Ed. 5(1983)40.
58. M. Lagas en J.H.G. Jonkman.
Invloed van voedsel op de biologische beschikbaarheid van theofylline na toediening van een nieuwe theofylline tablet met vertraagde afgifte.
Ned. T. v. Geneesk. 127(1983)1368.
59. J.H.G. Jonkman, H.G.M. Westenberg, N.V.M. Rijntjes, E. van der Kleijn and S.F. Lindeboom.
Whole body distribution of the quaternary ammonium compound thiazinamium (N-methylpromethazine) and promethazine in monkey and mice.
Arzneimittel Forschung/Drug Research 33(1983)223-228.
60. J.H.G. Jonkman, G.H. Koëter en W.Chr. Berg.
Geneesmiddelen met een therapeutisch belangrijke invloed op de farmacokinetiek van theofylline.
Pharm. Weekbl. 118(1983)185-190.
61. J.H.G. Jonkman, L.E. van Bork, B. Calvert, J.E. Greving, J. Wijsbeek, R.A. de Zeeuw and N.G.M. Orië.
Clinical pharmacokinetics of intramuscular thiazinamium methylsulphate.
Int. J. Clin. Pharmacol. Ther. Tox. 21(1983)454-459.
62. J.H.G. Jonkman and C.A. Hunt.
Ion pair absorption of ionized drugs - fact or fiction?
Pharm. Weekbl. Sci. Ed. 5(1983)41-48.
63. J.H.G. Jonkman and W.J.V. van der Boon.
Nocturnal theophylline plasma concentrations.
Lancet (1983)1278-1279.
64. J.H.G. Jonkman and L. Hendeles.
The theophylline-erythromycin interaction.
Chest 84(1983)309-310.

65. J.H.G. Jonkman, W.Chr. Berg and R.A. de Zeeuw.
'Dissolution models involving a pH-change: their correlation with absorption of theophylline from sustained release tablets', in 'Sustained release theophylline, a biopharmaceutical challenge to a clinical need' (F.W.H.M. Merkus and L. Hendeles, Eds.), Excerpta Medica, Amsterdam (1983)79-103.
66. R.J.J. Hageman, J.E. Greving, J.H.G. Jonkman and R.A. de Zeeuw.
High performance liquid chromatographic determination of reproterol in plasma using on-line trace enrichment and amperometric detection with a rotating working electrode.
J. Chromatog. Biom. Appl. 274(1983)239-253.
67. J.H.G. Jonkman, W.J.V. van der Boon, R. Schoenmaker and A. Holtkamp.
Plasma indomethacin assay by reversed-phase ion pair high pressure liquid chromatography.
Pharm. Weekbl. Sci. Ed. 5(1983)313-318.
68. M. Lagas and J.H.G. Jonkman.
Greatly enhanced bioavailability of theophylline on post-prandial administration of a sustained release tablet.
Eur. J. Clin. Pharmacol. 24(1983)761-767.
69. J.H.G. Jonkman, R.A. de Zeeuw and R. Schoenmaker.
'Interference with proposed selected method for theophylline HPLC-assay', in 'Selected Methods of Clinical Chemistry', Vol.10, (G.R. Cooper, Ed.), American Association for Clinical Chemistry, Washington D.C. (1983)166-167.
70. J.E. Greving, J.H.G. Jonkman, L.E. van Bork, N.G.M. Orie and R.A. de Zeeuw.
'Pharmacokinetics of thiazinamium methylsulphate and oxyphenonium bromide in relation to their pharmacodynamics', in 'Role of anticholinergic drugs in obstructive airway disease' (G. Schultze-Werninghaus and J.G. Widdicombe, Eds.), Gedon & Reuss, München (1983)127-138.
71. L.E. van Bork, J.H.G. Jonkman, J.E. Greving, N.G.M. Orie, R. Peset, K. de Vries and R.A. de Zeeuw.
'Pharmacodynamics of thiazinamium methylsulphate and oxyphenonium bromide and the differences in effects between an aerosol of oxyphenonium bromide or ipratropium bromide and a metered aerosol of oxyphenonium bromide', in 'Role of anticholinergic drugs in obstructive airway disease' (G. Schultze-Werninghaus and J.G. Widdicombe, Eds.), Gedon & Reuss, München (1983)139-155.

1984

72. J.H.G. Jonkman en G.H. Koëter.
Theofylline, een oud geneesmiddel, enkele nieuwe aspecten.
Ned. T. v. Geneesk. 128(1984)233.

73. D.D.S. Tang-Liu, J.H.G. Jonkman, K. Muir, M. Kunitani and S. Riegelman.
'A selective H.P.L.C. assay for simultaneous quantitation of fourteen methylxanthines and methyluric acids in urine', in 'Pharmacokinetics, a modern view'
(L.Z. Benet, G. Levy and B.L. Ferraiolo, Eds.), Plenum Press, New York/London
(1984)484-488.
74. N.H.G. Holford, P. Clements, P. Collier, N.G.M. Orie, L.E. van Bork and J.H.G. Jonkman.
'A pharmacokinetic model for thiazinamium in asthmatic patients', in Pharmacokinetics, a
modern view' (L.Z. Benet, G. Levy and B.L. Ferraiolo, Eds.), Plenum Press, New York/London
(1984)504-508.
75. G.H. Koëter, H. Meurs, J.H.G. Jonkman and K. de Vries.
Protective effect of choline theophyllinate on histamine, acetylcholine and propranolol induced
airflow obstruction.
Respiration 45(1984)139-146.
76. J.H.G. Jonkman and R.A. Upton.
Pharmacokinetic drug interactions with theophylline: a review.
Clin. Pharmacokin. 9(1984)309-334.
77. J.H.G. Jonkman, W.J.V. van der Boon, L.P. Balant, R. Schoenmaker and A. Holtkamp.
Chronopharmacokinetics of theophylline after sustained release and intravenous administration to
adults.
Eur. J. Clin. Pharmacol. 26(1984)215-222.
78. J.H.G. Jonkman, W.J.V. van der Boon, R. Schoenmaker and A. Holtkamp.
Clinical pharmacokinetic comparison of two indomethacin containing suppositories with different
vehicula.
Arzneimittel Forschung/Drug Research 34(1984)523-525.
79. J.H.G. Jonkman.
'Biopharmaceutical and pharmacokinetic drug interactions with theophylline', in 'Sustained
release theophylline in the treatment of chronic reversible airways obstruction'
(J.H.G. Jonkman, J.W. Jenne and F.E.R. Simons, Eds.).
Excerpta Medica, Amsterdam (1984)98-110.
80. G.H. Koëter, H. Meurs, J.H.G. Jonkman, J. Greving, J. Leferink, H.J. Sluiter and
R.A. de Zeeuw.
Protective effect of oral oxyphenonium bromide, terbutaline and theophylline against the
bronchial obstructive effects of inhaled histamine, acetylcholine and propranolol.
Eur. J. Clin. Pharmacol. 26(1984)435-441.
81. J.H.G. Jonkman, W.J.V. van der Boon, R. Schoenmaker, A. Holtkamp and J. Hempenius.
The effect of cefaclor on the clinical pharmacokinetics of theophylline.
Pharm. Weekbl. Sci. Ed. 6(1984)127.
82. J.H.G. Jonkman.
'In vitro' modelling and its relation to 'in vivo' absorption.
Br. J. Clin. Pract. 38(1984)Suppl. 35, 5-9.

83. W.J.V. van der Boon and J.H.G. Jonkman.
Drugs influencing theophylline disposition.
Br. J. Clin. Pract. 38(1984)Suppl. 35, 24-28.
84. J.H.G. Jonkman, W.J.V. van der Boon, R. Schoenmaker, A. Holtkamp and A.J. Thurkow-Luikens.
The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets.
Int. J. Clin. Pharmacol. Ther. Tox. 22(1984)506-510.
85. J.H.G. Jonkman, L.P. Balant, W.J.V. van der Boon, R. Schoenmaker and A. Holtkamp.
'Circadian variation in theophylline elimination', in 'Proceedings of the Second European Congress of Biopharmaceutics and Pharmacokinetics'
(J.M. Aiache and J. Hirtz, Eds.), Vol. I(1984)591-596.
86. J.H.G. Jonkman, W.J.V. van der Boon, R. Schoenmaker, A. Holtkamp and J. Hempenius.
'The influence of cefaclor on the clinical pharmacokinetics of theophylline', in 'Proceedings of the Second European Congress of Biopharmaceutics and Pharmacokinetics'
(J.M. Aiache and J. Hirtz, Eds.), Vol. III(1984)106-111.
87. J.H.G. Jonkman, W.J.V. van der Boon, R. Schoenmaker and A. Holtkamp.
'The influence of antacid on theophylline absorption from two sustained release preparations', in 'Proceedings of the Second European Congress of Biopharmaceutics and Pharmacokinetics' (J.M. Aiache and J. Hirtz, Eds.), Vol. III(1984)471-477.
88. J.H.G. Jonkman, R. Schoenmaker and J. Hempenius.
Bioanalysis of amoxicillin by ion pair column extraction and reversed-phase ion pair HPLC.
Pharm. Weekbl. Sci. Ed. 6(1984)254.
89. J.H.G. Jonkman, R. Schoenmaker, A.H. Holtkamp and J. Hempenius.
Rapid analysis of ibuprofen in plasma by column extraction and reversed-phase HPLC.
Pharm. Weekbl. Sci. Ed. 6(1984)254.
90. J.H.G. Jonkman and M.H. Smolensky.
'Chronopharmacology of theophylline, with special reference to age', in 'Biological Rhythms and Medications' (A. Reinberg, M. Smolensky and G. Labrecque, Eds.), Annual Review of Chronopharmacology, Vol. 1(1984)72-76. Pergamon Press, Oxford.
91. L.E. van Bork, J.H.G. Jonkman, J.E. Greving, N.G.M. Orié, R. Peset, K. de Vries and R.A. de Zeeuw.
'Relationship between plasma concentrations and the pulmonary and cardiac effects of three anticholinergics', in 'Receptors and COLD (chronic obstructive lung disease)',
(K.F. Kerrebijn, H.J. Sluiter and H.W.A. Wams, Eds.).
Excerpta Medica, Amsterdam (1984)202-207.

1985

92. J.H.G. Jonkman, W.J.V. van der Boon, R. Schoenmaker, A. Holtkamp and J. Hempenius.
No effect of cefaclor on theophylline pharmacokinetics.
Eur. J. Resp. Dis. 66(1985)47-49.

93. M. Lagas and J.H.G. Jonkman.
Food and a sustained release theophylline tablet on chronic dosing: bioavailability, peak-trough and trough-trough differences.
Pharm. Weekbl. Sci. Ed. 7(1985)10-14.
94. J.H.G. Jonkman, W.J.V. van der Boon, R. Schoenmaker A. Holtkamp and J. Hempenius.
Lack of effect of amoxicillin on theophylline pharmacokinetics.
Br. J. Clin. Pharmac. 18(1985)99-101.
95. P.-O. Fagerstrom, J.H.G. Jonkman and S.-O. Thuresson.
'An analysis of absorption rates following a single dose of slow-release theophylline administered before bedtime', in 'Sustained release theophylline and nocturnal asthma'
(A.F. Isles and P. von Wichert, Eds.), Excerpta Medica, Amsterdam (1985)108-115.
96. J.H.G. Jonkman en G. Grasmeijer.
Kunnen Ritmoforine Retard® tabletten gebroken worden zonder dat de retard eigenschappen verloren gaan? Wie weet!
Pharm. Weekbl. 120(1985)233-234.
97. J.H.G. Jonkman, W.J.V. van der Boon, L.P. Balant and J.Y. Le Cotonnec.
Food reduces the rate but not the extent of the absorption of theophylline from an aqueous solution.
Eur. J. Clin. Pharmacol. 28(1985)225-227.
98. J.H.G. Jonkman, W.J.V. van der Boon, R. Schoenmaker A. Holtkamp and J. Hempenius.
No influence of doxycycline on theophylline pharmacokinetics.
Ther. Drug. Monit. 7(1985)92-94.
99. J. Blanchard, S.J.A. Sawers, J.H.G. Jonkman and D.D.S. Tang-Liu.
Comparison of the urinary metabolite profile of caffeine in young and elderly males.
Br. J. Clin. Pharmac. 19(1985)225-232.
100. J.H.G. Jonkman.
Orale theofylline therapie.
Verslagen v.d. Belgische Vereniging voor Kindergeneeskunde 17(1985)133-143.
101. J.H.G. Jonkman, W.J.V. van der Boon, L.P. Balant and J.Y. Le Cotonnec.
No effect of food on single dose bioavailability of sustained release theophylline (Sabidal®); a comparison between Sabidal and choline theophyllinate solution.
Int. J. Pharm. 25(1985)113-117.
102. J.H.G. Jonkman, W.J.V. van der Boon, R. Schoenmaker, A.H. Holtkamp and J. Hempenius.
Clinical pharmacokinetics of amoxycillin and theophylline during co-treatment with both medicaments.
Chemother. 31(1985)329-335.

103. J.H.G. Jonkman, R. Schoenmaker, and J. Hempenius.
Determination of amoxicillin in plasma by ion pair column extraction and reversed-phase ion pair high performance liquid chromatography.
J. Pharm. Biomed. Anal. 3(1985)359-365.
104. J.H.G. Jonkman, W.J.V. van der Boon, R. Schoenmaker, A.H. Holtkamp and J. Hempenius.
Lack of influence of co-trimoxazole on theophylline pharmacokinetics.
J. Pharm. Sci. 74(1985)1103-1104.
105. J.H.G. Jonkman, R. Schoenmaker, A.H. Holtkamp and J. Hempenius.
Determination of ibuprofen in human plasma by solid phase extraction and reversed phase high performance liquid chromatography.
J. Pharm. Biomed. Anal. 3(1985)433-438.
106. M. Lagas and J.H.G. Jonkman.
Influence of food on the rate and extent of absorption of theophylline after single dose oral administration of a controlled release tablet.
Int. J. Clin. Pharmacol. Ther. Tox. 23(1985)424-426.
107. M.H. Smolensky, J.H.G. Jonkman and P.H. Scott.
Circadian variation in theophylline 'trough' serum concentrations.
Br. J. Clin. Pharmacol. 20(1985)718-719.
108. J.H.G. Jonkman, O. Borga, W.J.V. van der Boon, G. Grasmeijer and I. Ekman-Hakansson.
'Pharmacokinetics of enprophylline: relationship to age, sex, smoking habits and creatinine clearance', in 'Anti-asthma xanthines and adenosine' (K.-E. Andersson and C.G.A. Persson, Eds.), *Excerpta Medica, Amsterdam* (1985)248-254.
109. J. Kraan, J.H.G. Jonkman, O. Borga, I. Ekman-Hakansson, G.H. Koëter, H.J. Sluiter and R.A. de Zeeuw.
'Comparison of enprophylline and theophylline pharmacokinetics in patients with impaired hepatic or renal function', in 'Anti-asthma xanthines and adenosine' (K.-E. Andersson and C.G.A. Persson, Eds.), *Excerpta Medica, Amsterdam* (1985)267-270.
110. M.H. Smolensky, P.H. Scott, P.J. Barnes and J.H.G. Jonkman.
'The chronopharmacology and chronotherapy of asthma', in 'Biological Rhythms and Medications' (A. Reinberg, M. Smolensky and G. Labrecque, Eds.), *Annual Review of Chronopharmacology, Vol. 2*(1985)229-273. Pergamon Press, Oxford.

1986

111. J.H.G. Jonkman, W.J.V. van der Boon, R. Schoenmaker, A. Holtkamp and J. Hempenius.
Clinical pharmacokinetics of theophylline during co-treatment with cefaclor.
Int. J. Clin. Pharmacol. Ther. Tox. 24(1986)88-92.
112. M. Lagas and J.H.G. Jonkman.
Studies on the delivery mechanisms of theophylline from a sustained release tablet.
Drug Development and Industrial Pharmacy 12(1986)489-506.

113. J.H.G. Jonkman, H.M.P. Freie, W.J.V. van der Boon and G. Grasmeijer.
Single dose absorption profiles and bioavailability of two different salbutamol tablets.
Arzneimittel-Forschung/Drug Research 36(1986)1133-1135.
114. J.H.G. Jonkman, W.J.V. van der Boon, G. Grasmeijer and J. Holland.
No influence of breakfast on the disposition of the sustained release theophylline capsule
Dilatrane® A.P. 400 mg.
Eur. J. Resp. Dis. 69(1986)Suppl. 146, A81.
115. J.H.G. Jonkman.
'The role of food intake on day-night differences in theophylline absorption' in 'Biological
Rhythms and Medications' (A. Reinberg, M. Smolensky and G. Labrecque, Eds.), *Annual Review
of Chronopharmacology*, Vol. 3(1986)161-164.
116. J.H.G. Jonkman.
Therapeutic consequences of drug interactions with theophylline pharmacokinetics.
J. Allergy Clin. Immunol. 78(1986)736-742.
117. J.H.G. Jonkman en M. Lagas.
Theofylline preparaten met verlengde afgifte: invloed van voedsel op afgiftepatroon.
Pharm. Weekblad 121(1986)1231-1233.

1987

118. J.H.G. Jonkman, Ch.F. Gusdorf, W.J.V. van der Boon, G. Grasmeijer and J.N. Jedema.
Single dose bioavailability of two different digoxin tablets.
Arzneimittel-Forschung/Drug Research 37(1987)62-65.
119. B.E. Cabana, E.D. Purich, S.J. Veticaden, J.H.G. Jonkman, V.K. Prasad and R.L. Braun.
Phenotypic differences in dextromethorphan metabolism.
Clin. Pharmacol. Ther. 41(1987)159.
120. J.W. Wiechers, B.F.H. Drenth, R.A. de Zeeuw and J.H.G. Jonkman.
Percutaneous absorption and elimination of the penetration enhancer Azone in humans.
Pharm. Weekbl. Sci. Ed. 9(1987)151.
121. J.W. Wiechers, B.F.H. Drenth, R.A. de Zeeuw, J.H.G. Jonkman and R. Vaidyanathan.
In vivo percutaneous absorption and elimination of ¹⁴C-labeled Azone in humans.
Pharmaceutical Research 4(1987)S104.
122. J.H.G. Jonkman.
Food interactions with once-a-day theophylline preparations: a review.
Chronobiology International 4(1987)449-458.
123. N.H.G. Holford, P. Clements, P. Collier, N.G.M. Orie, L.E. van Bork and J.H.G. Jonkman.
Pharmacokinetics and pharmacodynamics of thiazinamium in asthmatic patients.
Eur. J. Clin. Pharmacol. 33(1987)237-242.

124. J.H.G. Jonkman, G. Grasmeijer and A. Holland.
Theophylline disposition after single-dose ingestion of a once-a-day preparation (Dilatrane® A.P. 400 mg) with and without breakfast.
Int. J. Clin. Pharmacol. Ther. Tox. 25(1987)633-637.
125. S.J. Vetticaden, B.E. Cabana, V.K. Prasad, E.D. Purich, J.H.G. Jonkman, R.A. de Zeeuw, R.L. Braun and L.J. Leeson.
Development of a controlled release dextromethorphan hydrobromide 'OROS' tablet: steady state plasma levels and food effects.
J. Pharm. Sci. 76(1987)S66.
126. J.W. Wiechers, B.F.H. Drenth, J.H.G. Jonkman and R.A. de Zeeuw.
Percutaneous absorption and elimination of the penetration enhancer Azone in humans.
Pharmaceutical Research 4(1987)519-523.
127. Ph. Guillet, V. Ascalone, G. Bianchetti, P. Padovani, J.F. Thiercelin, E. Bercoff, A. Crema, A. Meyrier, J.H.G. Jonkman and J.J. Thebault.
Influence of physiological and pathological factors on the pharmacokinetics of alpidem, a new imidopyridine anxiolytic agent.
'Proceedings of the Third European Congress of Biopharmaceutics and Pharmacokinetics' (J.M. Aiache and J. Hirtz, Eds.), Vol. III(1987)358-368.
128. J.H.G. Jonkman, W.J.V. van der Boon and G. Grasmeijer.
Intra-subject variability of theophylline pharmacokinetics after intravenous administration.
'Proceedings of the Third European Congress of Biopharmaceutics and Pharmacokinetics' (J.M. Aiache and J. Hirtz, Eds.) Vol. III(1987)425-428.

1988

129. J.H.G. Jonkman, W.J.V. van der Boon and G. Grasmeijer.
Comparison of the in vitro dissolution properties and in vivo steady-state pharmacokinetics of two sustained-release theophylline preparations.
Pharm. Weekbl. Sci. Ed. 10(1988)17-21.
130. B. Oosterhuis, J.H.G. Jonkman and F.A. Kerkhof.
Pharmacokinetic and pharmacodynamic comparison of a new controlled-release formulation of metoprolol with a traditional slow-release formulation.
Eur. J. Clin. Pharmacol. 33(1988)S15-S18.
131. J.H.G. Jonkman, G. Grasmeijer and G.H. Koëter.
Geneesmiddelen bij CARA.
Tijdschrift voor Therapie, Geneesmiddel en Onderzoek (Journal for Drug Therapy and Research) 13(1988)56-59.
132. J.H.G. Jonkman, V.W. Steijnmans, W. Beier, J.P. Yska, F.A. Kerkhof, O.E. de Noord and G. Grasmeijer.
Sustained release properties of the once daily theophylline capsule Euphyllong® as compared with Theo-Dur® tablets.
Int. J. Pharm. 43(1988)139-143.

133. J.H.G. Jonkman, A.S.C. Wijmenga, R.A. de Zeeuw, W.V.J. van der Boon, J.K. Beugelink, B. Oosterhuis and J.N. Jedema.
No effect of influenza vaccination on theophylline pharmacokinetics as studied by ultraviolet spectrophotometry, HPLC and EMIT assay methods.
Ther. Drug Monit. 10(1988)345-348.
134. J.H.G. Jonkman.
'A comparison of plasma profiles after Theo-Dur twice daily and Riker controlled release theophylline capsules once daily in volunteers' in 'Sustained release for once-a-day dosing' (A.J. Fairfax and P.A. Routledge, Eds.).
Research and Clinical Forums 10(1988)135-141.
135. J. Kraan, J.H.G. Jonkman, G.H. Koëter, C.H. Gips, P.E. de Jong, Th.W. van der Mark, I. Eckman and R.A. de Zeeuw.
The pharmacokinetics of theophylline and enprophylline in patients with liver cirrhosis and in patients with chronic renal disease.
Eur. J. Clin. Pharmacol. 35(1988)357-362.
136. J.H.G. Jonkman, A. Reinberg, B. Oosterhuis, O.E. de Noord, F. Kerkhof, Y. Motohashi, F. Levi, F. Dammacco and F. Caradente.
Dosing time and sex-related differences in the pharmacokinetics of cefodizime and in the circadian cortisol rhythm.
Chronobiologica 15(1988)89-102.
137. J.H.G. Jonkman, L. Borgström, W.J.V. van der Boon and O.E. de Noord.
Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.
Br. J. Clin. Pharmacol. 26(1988)285-293.
138. J. Kraan, L. Borgström, G.H. Koëter, M. Laseur, J.H.G. Jonkman and O.E. de Noord.
Creation of four consecutive instantaneous steady-state plasma concentration plateaus of theophylline and enprophylline by repeated infusions with exponentially decreasing delivery rates.
Eur. J. Clin. Pharmacol. 35(1988)657-661.
139. J.H.G. Jonkman.
'Clinical pharmacokinetic aspects of bronchodilator therapy', in 'New Developments in Mechanisms and Treatment of Bronchial Obstruction' (J.H. Dijkman, C.L.A. van Herwaarden, Chr. Hilvering and K.F. Kerrebijn, Eds.), 1988, 87-102.
140. J.H.G. Jonkman, A. Reinberg, B. Oosterhuis, O.E. de Noord, F.A. Kerkhof, Y. Motohashi, F. Lévi and F. Carandente.
'Dosing-time and sex related differences in the pharmacokinetics of cefodizime as well as in cortisol circadian rhythm' in 'Biological Rhythms and Medications' (A. Reinberg, M. Smolensky and G. Labreque, Eds.).
Annual Review of Chronopharmacology, Vol. 5(1988)247.
141. J.H.G. Jonkman.
'Geneesmiddelen-interacties in relatie met gastric asthma' in 'Gastric Asthma' (J.M.M. van den Bosch and J.H.S.M. Nadorp, Eds.), *Nieuwegein* (1988)147-158.

1989

142. F. Gimeno, R. van Veenen, W.Chr. Berg, E.J. Steenhuis, J.H.G. Jonkman and M.A. Weibel.
Chronopharmacodynamics and kinetics after symmetric and asymmetric multiple theophylline doses in patients with chronic obstructive pulmonary disease.
Int. J. Clin. Pharmacol. Ther. Tox. 27(1989)7-12.
143. S.J. Vetticaden, B.E. Cabana, V.K. Prasad, E.D. Purich, J.H.G. Jonkman, R.A. de Zeeuw, L.A. Ball, L.J. Leeson and R.L. Braun.
Phenotypic differences in dextromethorphan metabolism.
Pharmaceutical Research 6(1989)13-19.
144. J.H.G. Jonkman.
Food interaction with sustained-release theophylline preparations - a review.
Clinical Pharmacokinetics 16(1989)162-179.
145. J.H.G. Jonkman, V.W. Steijnans, W. Beier, W.J. van der Boon and G. Grasmeijer.
Sustained release properties of the once daily theophylline capsule BY912 as compared with Theo-24® capsules.
Biopharm. & Drug Disp. 10(1989)213-224.
146. V.W. Steijnans, R. Sauter, J.H.G. Jonkman, H.-U. Schulz, H. Stricker and H. Blume.
Bioequivalence studies: single vs. multiple dose.
Int. J. Clin. Pharmacol. Ther. Tox. 27(1989)261-266.
147. J.H.G. Jonkman, K.G. Nicholson, P.R. Farrow, M. Eckert, G. Grasmeijer, B. Oosterhuis, O.E. de Noord and T.W. Guentert.
Effects of α -interferon on theophylline pharmacokinetics and metabolism.
Br. J. Clin. Pharmacol. 27(1989)795-802.
148. D.N. Duong, J.H.G. Jonkman, P.B.M. Zuiderwijk, R.G.L. van Tol and P.J.G. Cornelissen.
Pharmacodynamics and tolerability of ULFS-49, a new specific bradycardic agent.
Eur. J. Clin. Pharmacol. 36(1989)Suppl. A, 164.
149. B. Oosterhuis, G. Nemiz, P.J.G. Cornelissen, P.B.M. Zuiderwijk, H.J. Jeurig, J.H.G. Jonkman, C.A.P.F. Su and R.G.L. van Tol.
Uricosuric effect of ambroxol.
Eur. J. Clin. Pharmacol. 36(1989)Suppl. A, 193.
150. F.A.E. Sollie, J. Dingemanse, J.H.G. Jonkman, H. Staudinger and V.W. Steijnans.
Investigation of the influence of caffeine on the pharmacokinetics of theophylline.
Eur. J. Clin. Pharmacol. 36(1989)Suppl. A, 263.
151. J. Hempenius, B. Staal, H.J. Jeurig, C.K. Mensink and J.H.G. Jonkman.
Determination of debrisoquine and 4-hydroxydebrisoquine in human urine by high performance liquid chromatography and fluorescence detection.
Pharm. Weekbl. Sci. Ed. 11(1989)Suppl. N, 5.

152. J. Wieling, J. Hempenius, P.M.J. Coenegracht, J.H.G. Jonkman, C.K. Mensink and D.A. Doornbos.
The introduction of mixture experimental design in the optimization of liquid extraction of drugs from biological matrices.
Pharm. Weekbl. Sci. Ed. 11(1989)Suppl. N, 11.
153. B. Oosterhuis and J.H.G. Jonkman.
Omeprazole: Pharmacology, Pharmacokinetics and Interactions.
Digestion 44(1989)Suppl. 1, 9-17.
154. G.H. Koëter, J. Kraan, M. Boorsma, J.H.G. Jonkman, Th.W. van der Mark.
Effect of theophylline and enprophylline on bronchial hyperresponsiveness.
Thorax 44(1989)1022-1026.
155. R.A. de Zeeuw and J.H.G. Jonkman.
Genetic differences in oxidative drug metabolism. An important factor in the interpretation of analytical results in intoxications.
In: 'Forensic Toxicology', Proceedings of the 25th International Meeting of the International Association of Forensic Toxicologists (D.R.A. Uges and R.A. de Zeeuw, Eds.) 1989, 53-64.

1990

156. J.W. Wiechers, B.F.H. Drenth, J.H.G. Jonkman and R.A. de Zeeuw.
Percutaneous absorption, metabolic profiling and excretion of the penetration enhancer Azone after multiple dosing of an Azone-containing triamcinolone acetonide cream in humans.
J. Pharm. Sci. 79(1990)111-115.
157. B. Oosterhuis, J.H.G. Jonkman, P.B.M. Zuiderwijk and F.A.E. Sollie.
A pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK with a conventional slow release preparation.
J. Clin. Pharmacol. 30(1990)S33-S38.
158. F. Gimeno, E.J. Steenhuis and J.H.G. Jonkman.
Effect of theophylline on cortisol plasma concentrations in patients with chronic obstructive pulmonary disease.
Int. J. Clin. Pharmacol. Ther. Tox. 28(1990)139-143.
159. J. Hempenius, B. Staal, H.J. Jeurig, C.K. Mensink and J.H.G. Jonkman.
Determination of debrisoquine and 4-hydroxydebrisoquine in human urine by high performance liquid chromatography and fluorescence detection.
J. Liq. Chrom. 13(1990)1627-1636.
160. J. Hempenius, J. Wieling, J.H.G. Jonkman, O.E. de Noord, P.M.J. Coenegracht and D.A. Doornbos.
Development of a laboratory robotic system for automated bioanalytical methods.
- I. The determination of theophylline in human plasma: a comparison between the robotized and manual method.
J. Pharm. Biomed. Anal. 8(1990)313-320.

161. J. Wieling, J. Hempenius, H.J. Jeuring, J.H.G. Jonkman, P.M.J. Coenegracht and D.A. Doornbos.
Development of a laboratory robotic system for automated bioanalytical methods.
- II. A robot computer program for guarding totally automated bioanalytical methods.
J. Pharm. Biomed. Anal. 8(1990)577-582.
162. J.W. Wiechers, B.F.H. Drenth, J.H.G. Jonkman and R.A. de Zeeuw.
Percutaneous absorption of triamcinolone acetonide from creams with and without Azone® in humans in vivo.
Int. J. Pharm. 66(1990)53-62.

1991

163. B. Oosterhuis and J.H.G. Jonkman.
Single dose versus multiple dose studies in the evaluation and validation of controlled/modified release formulations.
In: Controlled/modified release products: recommendation in support of EC-guidelines (H. Blume, U. Gundert-Remy, H. Moller, Eds.) 1991, 51-65 (Paperback APV; band 29)
Stuttgart: Wissenschaftliche Verlagsgesellschaft.
164. J. Wieling, J.P. de Kleijn, C.K. Mensink and J.H.G. Jonkman.
'Robots in het laboratorium'
In: Computers in de chemie (J.W.A. Klaesens, Ed.)
Stichting Centra voor Micro-Elektronica/Koninklijke Nederlandse Chemische Vereniging, 1991, 94-115.
165. J.H.G. Jonkman, F.A.E. Sollie, R. Sauter and V.W. Steinijans.
The influence of caffeine on steady-state pharmacokinetics of theophylline.
Clin. Pharmacol. Ther. 49(1991)248-255.
166. J. Wieling, J. Schepers, J. Hempenius, C.K. Mensink and J.H.G. Jonkman.
Optimization of chromatographic selectivity of twelve sulphonamides in reversed-phase high performance liquid chromatography using mixture designs and multi-criteria decision making.
J. Chromatog. 545(1991)101-114.
167. J.H.G. Jonkman and B. Oosterhuis.
Food and bioavailability and bioequivalence studies.
In: Drug-drug and drug-food interactions (D.D. Breimer and F.W.H.M. Merkus, Eds.)
1991, 131-138.
Boerhave Committee for Postgraduate Medical Education, Leiden University, The Netherlands.
168. J.H.G. Jonkman, G. Bianchetti, G. Grasmeijer, B. Oosterhuis, J.F. Thiercelin, J.P. Thénot, Ph. Guillet and P.L. Morselli.
Clinical pharmacokinetics and tolerability of alpidem in healthy subjects given increasing single doses.
Eur. J. Clin. Pharmacol. 41(1991)369-371.

169. B. Oosterhuis, J.H.G. Jonkman, T. Anderson, P. Zuiderwijk and J.N. Jedema.
Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose.
Br. J. Clin. Pharmac. 32(1991)569-572.
170. P.N.M. van Heiningen, M.D. Eve, B. Oosterhuis, J.H.G. Jonkman, H. de Bruin, J.A.R.J. Hulsman, A. Richens and P. Klosterskov Jensen.
The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine.
Clin. Pharmacol. Ther. 50(1991)410-419.
171. C.G. Miller, R.E.S. Bullingham and J.H.G. Jonkman.
Bioavailability of two formulations of naproxen enteric-coated 500-mg tablets in fasting and postprandial male volunteers following a single dose.
Curr. Ther. Res-Clin. & Exp. 49(1991)740-749.
172. G. Montay, R. Bruno, J.C. Vergniol, J. Rey, A. Frydman, P.A.M. Peeters, I. Dhont and J.H.G. Jonkman.
Pharmacokinetics of sparfloxacin after repeated administration in healthy elderly volunteers.
Agents And Chemotherapy 31(1991)198.
173. G. Storm, B. Oosterhuis, J. Bron, A.J. Wittebrood, A.P. de Jong and J.H.G. Jonkman.
A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers.
Biopharm. & Drug Disp. 12(1991)661-672.
174. O.R. Leeuwenkamp, H.W. Visscher, E. Louwerens, K.J. van Aubel and J.H.G. Jonkman.
A comparative study on the steady-state pharmacokinetics of controlled-release and immediate-release diltiazem tablet preparations.
Pharm. Weekbl. Sci. Ed. 13(1991)Suppl. E, 4.
175. H.W. Visscher, J.J. van Lier, G.A. Roders and J.H.G. Jonkman.
A comparative study on the adrenal suppressive effect of budesonide and betamethasone dipropionate, both applied as creams.
Pharm. Weekbl. Sci. Ed. 13(1991)Suppl. M, 4.
176. C. Güzelhan, H.J.M.J. Crijns, P.A.M. Peeters, J.H.G. Jonkman and D. Hartmann.
Pharmacological activity (inhibition of fat absorption) and tolerability in healthy volunteers of tetrahydrolipstatin (THL) - specific lipase inhibitor.
Int. J. Obesity 15(1991)Suppl. 1, 29.

1992

177. V.W. Steijnijans, R. Sauter, J.H.G. Jonkman, H.-U. Schulz, H. Stricker and H. Blume.
Bioequivalence studies: single vs. multiple dose.
Int. J. Clin. Pharmacol. Ther. Tox. 30(1992)Suppl. 1, S31-S36.
(Is identical to no. 147)

178. J. Wieling, P.M.J. Coenegracht, C.K. Mensink, J.H.G. Jonkman and D.A. Doornbos.
Selection of robust combinations of extraction liquid composition and internal standard.
Monte Carlo simulation of improvement of assay methods with liquid-liquid extraction prior to high-performance liquid chromatography.
J. Chromatog. 594(1992)45-64.
179. J. Wieling, A.N. Grimberg, C.K. Mensink and J.H.G. Jonkman.
The effect of experimental error of analytical assay methods on the determination of pharmacokinetic parameters: a Monte Carlo simulation.
Pharm. Weekbl. Sci. 14(1992)A10.
180. V.W. Steinijans, D. Hauschke and J.H.G. Jonkman.
Controversies in bioequivalence studies.
Clinical Pharmacokinetics 22(1992)247-253.
181. R.A. de Zeeuw, D. Eikema, J.P. Franke and J.H.G. Jonkman.
A rapid thin layer chromatographic procedure to identify poor and extensive oxidative drug metabolizers in man using dextromethorphan.
Pharmazie 47(1992)346-348.
182. B. Oosterhuis, J.H.G. Jonkman, T. Andersson and P.B.M. Zuiderwijk.
No influence of single intravenous doses of omeprazole on theophylline elimination kinetics.
J. Clin. Pharmacol. 32(1992)470-475.
183. T.W. Guentert, M. Schmitt, J. Dingemans and J.H.G. Jonkman.
Influence of moclobemide on ibuprofen-induced faecal blood loss.
Psychopharmacology 106(1992)S40-S42.
184. G. Roncari, Ch. Ponelle, R. Zumbrennen, A. Geunzi, J. Dingemans and J.H.G. Jonkman.
Percutaneous absorption of amorolfine following a single topical application of an amorolfine cream formulation.
Clin. & Exp. Derm. 17(1992)Suppl. 1, 33-36.
185. E.J. van Hoogdalem, B. Oosterhuis, H. de Bruin, N.R. Hefting and J.H.G. Jonkman.
Bioequivalentie en biologische beschikbaarheid.
Pharm. Weekbl. 127(1992)1051-1053.
186. T.W. Guentert, M. Schmitt, J. Dingemans, L. Banken, J.H.G. Jonkman and B. Oosterhuis.
Unaltered ibuprofen-induced faecal blood loss upon coadministration of moclobemide.
Drug Metabolism and Drug Interactions 10(1992)307-322.

1993

187. W. Roth, E. Bauer, G. Heinzl, P.J.G. Cornelissen, R.G.L. van Tol, J.H.G. Jonkman and P.B.M. Zuiderwijk.
Zatebradine: Pharmacokinetics of a novel heart-rate-lowering agent after intravenous infusion and oral administration to healthy subjects.
J. Pharm. Sci. 82(1993)99-106.

188. D. Hartmann, C. Güzelhan, H.J.M.J. Crijns, P.A.M. Peeters, P. Persson and J.H.G. Jonkman. Comparison of galenic formulations of Orlistat (Tetrahydrolipstatin): a pharmacological approach. *Drug Invest.* 5(1993)44-50.
189. J. Wieling, H. Dijkstra, C.K. Mensink, J.H.G. Jonkman, P.M.J. Coenegracht, C.A.A. Duineveld and D.A. Doornbos. Chemometrics in bioanalytical sample preparation: A fractionated combined mixture and factorial design for the modelling of the recovery of five tricyclic amines from plasma after liquid-liquid extraction prior to high-performance liquid chromatography. *J. Chromatog.* 629(1993)181-199.
190. H.J.G.M. Crijns, B. Oosterhuis, A.C.P. Wiesfeld, H. de Bruin, C.K. Mensink, J.H.G. Jonkman, C. Kozma and K.I. Kie. Electrophysiologic and pharmacokinetic profile of the new antiarrhythmic drug TYB-3823 in humans. *J. Cardiovasc. Pharmacol.* 21(1993)1-6.
191. B. Oosterhuis, G. Storm, P.J.G. Cornelissen, C.A.P.F. Su, F.A.E. Sollie and J.H.G. Jonkman. Dose-dependent uricosuric effect of ambroxol. *Eur. J. Clin. Pharmacol.* 44(1993)237-241.
192. J. Wieling, P.M.J. Coenegracht, D.A. Doornbos and J.H.G. Jonkman. Robustness testing of an optimized reversed-phase high-performance liquid chromatographic system for the separation of six sulphonamides using rules of error propagation. *J. Chromatog.* 635(1993)195-202.
193. B. Oosterhuis and J.H.G. Jonkman. Pharmacokinetic studies in healthy volunteers in the context of in vitro/in vivo correlations. *Eur. J. Drug. Met. Pharmacokin.* 18(1993)19-30.
194. M.-L. Huang, A. van Peer, R. Woestenborghs, J. Heykants, R. de Coster, Z. Zylicz, H.W. Visscher, H.J.G. de Wilde and J.H.G. Jonkman. Pharmacokinetics of a novel antipsychotic agent risperidone and the prolactin response in volunteers. *Eur. J. Drug Met. Pharmacokin.* 18(1993)Suppl. 107.
195. C.R. Jones, R.J. Ambros, H.J. Rapold, B. Steiner, T. Weller, P. van Heiningen, H.J.M.J. Crijns, J.H.G. Jonkman and P. Hadvary. RO 44-9883: A Novel non peptide GPIIb/IIIa antagonist in man. *Thrombosis and Haemostasis* 69(1993)560.
196. P.N.M. van Heiningen, H.R. Schwietert, J.M. Kortboyer, F.A.E. Sollie, C. Pirabe, P. Desché and J.H.G. Jonkman. Comparison of the pharmacokinetics of trimetazidine in elderly and young volunteers during multiple dose administration of a new sustained release formulation. *Pharmacy World & Science* 15(1993)Suppl. E, 7.

197. B. Oosterhuis and J.H.G. Jonkman.
Advantages and Disadvantages of Reformulation of Older Drugs.
Clin. Pharmacokinet. 25(1993)165-171.
198. M.-L. Huang, A. van Peer, R. Woestenborghs, R. de Coster, J. Heykants, A.A.I. Jansen, Z. Zyllicz, H.W. Visscher and J.H.G. Jonkman.
Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.
Clin. Pharmacol. Ther. 54(1993)257-268.
199. F.W.H.M. Merkus, J.H.G. Jonkman, B. Oosterhuis and J.W.P.M. Overdiek.
Drug-food interactions.
In: Drug-drug and drug-food interactions (D.D. Breimer and F.W.H.M. Merkus, Eds.), 1993, 71-87. Leiden/Amsterdam Institute for Drug Research (LAIDR), Leiden, The Netherlands.
200. B. Oosterhuis and J.H.G. Jonkman.
Significance of the reference product in bioequivalence evaluations with highly variable drugs: pharmaceutical quality, variability, biopharmaceutical characteristics.
In: Bio-International: bioavailability, bioequivalence and pharmacokinetics; proceedings of the international conference of F.I.P. Bio-International '92, Bad Homburg, Germany, 1992 (K.K. Midha and H.H. Blume Eds.) 1993, 107-117. Medpharm GmbH Scientific Publishers, Stuttgart.
201. B. Steiner, C.R. Jones, P.N.M. van Heiningen, J.H.G. Jonkman, R.C. Carroll and W.C. Kouns.
TRAP induced *ex vivo* platelet aggregation might be a useful method to predict an anti-thrombotic efficacy.
Blood 82(1993)Suppl. 1, 284A.

1994

202. S. Selim, F.J. Preiss, J.H.G. Jonkman and K.L. Gabriel.
Dermal absorption and mass balance of MGK 326 and reformulated MGK 326 in human volunteers.
J. of Tox.- Cutaneous and Ocular Tox. 13(1994)83-96.
203. C.A.P.F. Su, P.N.M. van Heiningen, J.J. van Lier, H. de Bruin, K.U. Kirchgaessler, P.J.G. Cornelissen and J.H.G. Jonkman.
Pharmacodynamics of the A II antagonist BIBR0277SE.
Clin. Pharmacol. Ther. 55(1994)205.
204. Y.S. Tuininga, H.J.G.M. Crijns, B. Oosterhuis, A.C.P. Wiesfeld, L.M. van Wijk, F. Albronda, H. de Bruin, J.H.G. Jonkman, C. Kozma and K.I. Lie.
Hemodynamic effects of the new antiarrhythmic agent restacorin in patients with normal and decreased left ventricular function.
J. of Cardio. Pharmacol. 23(1994)408-414.
205. J. Götz, R. Sauter, V.W. Steinijans and J.H.G. Jonkman.
Steady-state pharmacokinetics of a once-daily theophylline formulation (Euphylong®) when given twice daily.
Int. J. Clin. Pharmacol. Ther. 32(1994)168-173.

206. O.R. Leeuwenkamp, H.W. Visscher, C.K. Mensink and J.H.G. Jonkman.
A comparative study of the steady-state pharmacokinetics of immediate-release and controlled-release diltiazem tablets.
Eur. J. Clin. Pharmacol. 46(1994)243-247.
207. Y.S. Tuininga, H.J.G.M. Crijns, C. Kozma, G. Rabloczky, J.H.G. Jonkman and K.I. Lie.
Restacorin, a new antiarrhythmic drug: A review of its electrophysiologic and hemodynamic properties.
Int. J. Clin. Pharmacol. Ther. 32(1994)278-281.
208. G. Storm, B. Oosterhuis, F.A.E. Sollie, H.W. Visscher, W. Sommer, H. Beitinger and J.H.G. Jonkman.
Lack of pharmacokinetic interaction between vinpocetine and oxazepam.
Br. J. Clin. Pharmacol. 38(1994)143-146.
209. J. Hempenius, G. Hendriks, J. Hingstman, C.K. Mensink, J.H.G. Jonkman and C.C. Lin.
An automated analytical method for the determination of felbamate in human plasma by robotic sample preparation and reversed-phase high performance liquid chromatography.
J. Pharm. B. 12(1994)1443-1451.
210. J. Wieling, J.H.G. Jonkman, J. Hempenius and C.K. Mensink.
Integration of robotics and chemometrics for the automated optimisation of drug extractions.
Chemometrics and Intelligent Laboratory Systems 25(1994)355-366.
211. K. Wesnes, E. Neuman, H.J.G. de Wilde, M. Malbezin, H.J.M.J. Crijns, J.H.G. Jonkman and D. Guez.
Pharmacodynamic effects of repeated oral administration of 4 different doses of S12024-2 (Cognitive Enhancer) in 36 healthy volunteers.
Neurobiol. Aging 15(1994)Suppl. 1, 100.
212. S. Snel, J.H.G. Jonkman, P.N.M. van Heiningen, J.A. Jansen and H.B. Mengel.
Tiagabine: Evaluation of Risk of Interaction with Cimetidine in Healthy Male Volunteers.
Epilepsia 35(1994)Suppl. 7, 74.
213. T.A. Hissink Muller, W. Russchen and J.H.G. Jonkman.
CRO experiences with GCP in The Netherlands.
Good Clinical Practice Journal 1(1994)40-41.
214. J. Shah, R. Bullingham, J.H.G. Jonkman, J. Curd, R. Taylor and A. Fratis.
PK-PD interaction of ketorolac and furosemide in healthy volunteers in a normovolemic state.
Clin. Pharmacol. Ther. 55(1994)198.
215. A. Leliboux, M. Teule, A. Frydman, B. Oosterhuis and J.H.G. Jonkman.
The effect of diet on the single-dose and multiple-dose pharmacokinetics of sustained-release ketoprofen.
Eur. J. Clin. Pharmacol. 47(1994)361-366.

216. P.N.M. van Heiningen, J.J. van Lier, H. de Bruin, C.A.P.F. Su, K.U. Kirchgässler, P.J.G. Cornelissen and J.H.G. Jonkman.
Single dose study on the pharmacodynamics and pharmacokinetics of the angiotensin II antagonist BIBR0277SE.
Pharmacy World & Science 16(1994)Suppl. D, 4.

1995

217. B. Oosterhuis and J.H.G. Jonkman.
Bioanalysis in the context of biopharmaceutical research: Quantitive and qualitative requirements.
Pharm. Weekbl. 130(1995)233-239.
218. A.J.P.M. Smout, J.H.G. Jonkman, P.A.M. Peeters and H. de Bruin.
Effect of an evening dose of regular and effervescent formulations of ranitidine or cimetidine on intragastric pH in healthy volunteers.
Aliment. Pharmacol. Ther. 9(1995)51-56.
219. J. Dingemanse, J. Kneer, B. Fotteler, H. Groen, P.A.M. Peeters and J.H.G. Jonkman.
Switch in treatment from tricyclic antidepressants to moclobemide: A new generation monoamine oxidase inhibitor.
J. Clin. Psychopharm. 15(1995)41-48.
220. B. Oosterhuis, J. Wemer and J.H.G. Jonkman.
Metabolisme in Fase I onderzoek: toepassing van nieuwe inzichten in (oxidatief) metabolisme bij Fase I onderzoek met nieuwe geneesmiddelen.
Conceptuur 2(1995)8-9.
221. M.G.F. Gerrits, J. Wemer and J.H.G. Jonkman.
Deelname van vrouwen aan klinisch geneesmiddelenonderzoek.
Conceptuur 3(1995)12-13.
222. A. Verhagen, J.T. Ebels, F.A.E. Sollie, A.A. Dogterom and J.H.G. Jonkman.
Pharmacokinetics and pharmacodynamics of rDNA-hGH after administration by jet-injection: A comparison with conventional needle-injection.
J. Endocrinol. 144(1995)53.
223. H. Groen, H.L. Moesker, O.R. Leeuwenkamp, F.A.E. Sollie and J.H.G. Jonkman.
No pharmacokinetic interaction between theophylline and BAY X 1005, a new inhibitor of leukotriene synthesis.
Pharmacy World & Science 17(1995)Suppl. A, 3.
224. H.J.G. de Wilde, K. Wesnes, E. Neuman, M. Malbezin, I. Castagné, D. Geuz, H.J.M.J. Crijns and J.H.G. Jonkman.
Preliminary pharmacodynamic effects of S12024-2 (cognitive enhancer) during repeated oral administration at 4 dose levels in 36 healthy elderly volunteers.
Pharmacy World & Science 17(1995)Suppl. A, 6.
225. J.T. Ebels, P. Dogterom, B. Oosterhuis, G. Bianchetti and J.H.G. Jonkman.
Comparison of biopharmaceutic characteristics of four diltiazem controlled release preparations.
Pharmacy World & Science 17(1995)Suppl. D, 5.

226. E.W.J. Groen, H.R. Schwietert, S.P. van Marle, F.A.E. Sollie, J. Wemer, K. Francis, A. Metcalfe and J.H.G. Jonkman.
An evaluation of single dose administration of recombinant human parathyroid hormone (rhPTH (1-84)) in healthy post-menopausal female volunteers.
Pharmacy World & Science 17(1995)Suppl. D, 11.
227. A.A. Dogterom, N.R. Hefting, D. Kanner, B. Jesussek, E. Ezra and J.H.G. Jonkman.
Jet injected growth hormone: *in vitro* and *in vivo* comparison with conventional injection.
Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 22(1995)490-491.
Controlled Release Society, Inc., Deerfield, IL 60015, U.S.A., 1995.
228. B.Oosterhuis, M.D. Brannan, H. Groen, P.A.M. Peeters, J. Hempenius, E. Radwanski, A.A. Nomeir, M.B. Affrime and J.H.G. Jonkman.
Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur®).
Annals of Allergy, Asthma & Immunology, 74(1995)157-161.
229. H.J. Möbius, A. Gerebtzoff, J.H.G. Jonkman, A. Racine-Poon and C.H. Gleiter.
CGP 36 742, an orally active gaba_B antagonist: gender-related pharmacokinetics in healthy elderly volunteers.
Thérapie 50 (1995) Suppl., 30.
230. J.H.G. Jonkman, H.W. Visscher, J.J. van Lier, J. Wemer, B. Stieren and H. Müller-Pelzer.
Tolerability and pharmacokinetics of dexverapamil after intravenous administration of 250 to 625 mg over 6 hours.
Thérapie 50 (1995) Suppl., 524.
231. E.W.J. Groen, H.R. Schwietert, S.P. van Marle, F.A.E. Sollie, J. Wemer, K. Francis, A. Metcalfe and J.H.G. Jonkman.
Multiple dose administration of recombinant human parathyroid hormone (rhPTH (1-84)) in healthy postmenopausal volunteers.
Thérapie 50 (1995) Suppl., 525.
232. H.W. Visscher, J.T. Ebels, G.A. Roders and J.H.G. Jonkman.
Randomised crossover comparison of adrenal suppressive effects of dermal creams containing glucocorticosteroids.
Eur. J. Clin. Pharmacol. 48(1995)123-125.
233. A. Verhagen, J.T. Ebels, A.A. Dogterom and J.H.G. Jonkman.
Pharmacokinetics and pharmacodynamics of a single dose of recombinant human growth hormone after subcutaneous administration by jet-injection: comparison with conventional needle-injection.
Eur. J. Clin. Pharmacol. 49(1995)69-72.
234. J.H.G. Jonkman, E.W.J. Groen, H.R. Schwietert, S.P. van Marle, K. Francis and A. Metcalfe.
First administration of recombinant human parathyroid hormone (rhPTH (1-84)) in healthy postmenopausal volunteers.
Pharm. Research 12(1995)S106.

235. S. Selim, K.L. Gabriel, J.H.G. Jonkman and F.J. Preiss.
Absorption and mass balance of MGK R11 and MGK R11 formulated with DEET, MGK 264 and MGK 326 following an 8 hour dermal exposure in human volunteers.
J. Tox. - Cut. & Ocul. Tox. 14(1995)151-167.
236. P. Dogterom, B. Oosterhuis, J.T. Ebels and J.H.G. Jonkman.
Inhaled fluticasone propionate induces greater cortisol suppression compared to budesonide. A dose response study using pressurized metered dose inhalers (PMDIs).
Eur. Respir. J. 8(1995)Suppl. 19, 303
237. H.J.G. de Wilde, K. Wesnes, E. Neuman, M. Malbezin, I. Castagne, D. Guez, H.J.M.J. Crijns and J.H.G. Jonkman.
Cognitive enhancing effects of S1224-2 during repeated oral administration at 4 dose levels in 36 healthy elderly volunteers.
Eur. J. Clin. Invest. 25(1995)Suppl. 2, 65.
238. H. Mengel, J.A. Jansen, K. Sommerville, J.H.G. Jonkman, K. Wesnes, A. Cohen, G.F. Carlson, R. Marshall, S. Snel, J. Dirach and H. Kastberg.
Tiagabine - evaluation of the risk of interaction with theophylline, warfarin, digoxin, cimetidine oral-contraceptives, triazolam, or ethanol.
Epilepsia 36(1995)Suppl. 3, 160.
- 238A. J. Wieling, B. Oosterhuis and J.H.G. Jonkman.
Consequences of Variation of Bioanalytical Methods on Estimation of Pharmacokinetic Parameters-Simulation and Laboratory Experience.
In: *Bio-International 2: Bioavailability, bioequivalence and pharmacokinetics; International Conference of F.I.P. 'Bio-International '94'*, Munich, Germany, 1994 (H.H. Blume, K.K. Midha, Eds) 1995, 371-385.
Medpharm GmbH Scientific Publishers, Stuttgart.

1996

239. J. Wieling, G. Hendriks, W.J. Tamminga, J. Hempenius, C.K. Mensink, B. Oosterhuis and J.H.G. Jonkman.
Rational experimental design for bioanalytical methods validation. Illustration using an assay method for total captopril in plasma.
Journal of Chromatography A, 730(1996)381-394.
240. N.C. van de Merbel, A.P. Tinke, B. Oosterhuis and J.H.G. Jonkman.
De opmars van LC-MS in de bioanalyse.
Conceptuur, 8(1996)4-5.
241. P. Dogterom, J.J. van Lier, J. Wemer, S. Sabo, P. Glue and J.H.G. Jonkman.
Comparative bioavailability study on interferon alpha-2b administered subcutaneously: lyophilized powder versus a human serum albumin-free sterile solution.
Eur. J. Drug Met. Pharmacokin. 21(1996) Suppl. 44.

242. C.P.H.M. Spiertz, I.J. Terpstra, L.E. Pope, J.F. Marcelletti, P.N.M. van Heiningen, W.J. Tamminga, J.H.G. Jonkman and E.J. van Hoogdalem.
Pharmacokinetics and metabolism of the antiviral agent n-docosanol after single oral and topical dosing in man.
Eur. J. Drug Met. Pharmacokin. 21(1996) Suppl. 141.
243. H. Groen, H.L. Moesker, O.R. Leeuwenkamp, F.A.E. Sollie and J.H.G. Jonkman.
No pharmacokinetic or pharmacodynamic interaction between theophylline and the leukotriene biosynthesis inhibitor BAY x 1005.
J. Clin. Pharmacol 36(1996)639-646.
244. J. Wemer and N.R. Hefting.
New initiatives in regulatory sciences.
Pharmaceutisch Weekblad 42(1996)1198-1199.
245. H.R. Schwietert, P.A.M. Peeters, J. Dingemans, J.F. Thiercelin, J. Necciari, H. de Bruin and J.H.G. Jonkman.
Multiple dose pharmacokinetics of tiludronate in healthy volunteers.
Eur. J. Clin. Pharmacol 51(1996)175-181.
246. C. Weber, R. Schmitt, H. Birnboeck, G. Hopfgartner, S.P. van Marle, P.A.M. Peeters, J.H.G. Jonkman and C-R. Jones.
Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.
Clin. Pharmacol. Ther. 60(1996)124-137.
247. R. Colucci, P. Glue, C. Banfield, P. Reidenberg, J. Meehan, E. Radwanski, C. Korduba, C. Lin, P. Dogterom, T. Ebels, G. Hendriks, J.H.G. Jonkman and M. Affrime.
Effect of felbamate on the pharmacokinetics of clonazepam.
American Journal of Therapeutics 3(1996)294-297.
248. C.A.P.F. Su, J.J. van Lier, H.R. Schwietert, J. Stangier, P.J.G. Cornelissen and J.H.G. Jonkman.
Influence of telmisartan, a non-peptide angiotensin II (A II) receptor antagonist, on steady state pharmacodynamics and pharmacokinetics of warfarin in healthy subjects.
Naunyn-Schmiedeberg's Arch. Pharmacol. 353(1996)Suppl. 4, 155.
249. J. Wieling.
Robotics in the Pharmaceutical and Biomedical Laboratory.
In: Encyclopedia of Pharmaceutical Technology, Volume 13(1996)409-452.
(J. Swarbrick and J.C. Boylan, Eds.), M. Dekker, Inc., New York, Basel, Hongkong.
250. C. Weber, Y.K. Tam, G. Schmidtke-Schrezemeier, J.H.G. Jonkman and P. van Brummelen.
Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers.
Eur. J. Clin. Pharmacol. 51(1996)87-90.

251. P.A.M. Peeters, H.J.M.J. Crijns, W.J. Tamminga, F.A.E. Sollie, G. Kieffer, J. Necciari and J.P. Dickinson, J.H.G. Jonkman.
Absence of pharmacokinetic interaction between the novel antiplatelet agent, clopidogrel, and digoxin.
European Heart Journal 17(1996) 160, P913.

1997

252. H.R. Schwieter, E.W.J. Groen, F.A.E. Sollie and J.H.G. Jonkman.
Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers.
Clin. Pharmacol. Ther. 61(1997)360-376.
253. K.A. Wesnes, R.A. Faleni, N. Hefting, G. Hoogsteen, J. Houben, J. Leonard, O. Petrini and J.J. van Lier.
The cognitive, subjective and physical effects of Gincosan® in healthy volunteers with neurasthenic complaints.
Proceedings of the British Psychological Society 5(1)(1997)50.
254. J.J. van Lier, P.N.M. van Heiningen and M. Sunzel.
Absorption, metabolism and excretion of ¹⁴C-candesartan and ¹⁴C-candesartan cilexetil in healthy volunteers.
Journal of Human Hypertension 11(1997)Suppl 2,27-28.
255. J.H.G. Jonkman, J.J. van Lier, P.N.M. van Heiningen, R. Lins, R. Sennewald and A. Högemann.
Pharmacokinetic drug interaction studies with candesartan cilexetil.
Journal of Human Hypertension 11(1997)Suppl 2,31-35.
256. J. Wemer, W. Tamminga, B. Oosterhuis, B. Wilffert, J.H.G. Jonkman, L. de Ley, R. de Zeeuw, R. Herings, S. Vranckx, B. Drenth and J. Meulenbelt.
Genotyping in relation to pharmacokinetics and pharmacodynamics.
Conceptuur 14(1997)34-36.

1998

257. J. Wieling and J.H.G. Jonkman.
LC-MS/MS: An indispensable tool for drug development.
Pharmaceutical Manufacturing International (1998)29.
258. B. Wilffert, W.J. Tamminga, J. Wemer, B. Oosterhuis, J. Wieling, J.H.G. Jonkman, L.F.M.H. de Ley, R.A. de Zeeuw.
Distribution of CYP2D6 and CYP2C19 phenotypes in Dutch male and female volunteers in clinical pharmacology studies.
Naunyn-Schmiedeberg's Archives of Pharmacology, Suppl. to Vol. 357, 4(1998)R176.
259. J.H.G. Jonkman and G.J. Bijloo.
Good Laboratory Practice: Niet Gedocumenteerd=Niet Gedaan.
Folia Pharmaceutica 85(1998)37-39.

260. N.C. van de Merbel, G. Wilkens, S. Fowles, B. Oosterhuis and J.H.G. Jonkman.
LC-phases improve, but not all assays do: metformin bioanalysis revisited.
Chromatographia 47(1998)542-546.
261. N.C. van de Merbel, A.P. Tinke, B. Oosterhuis, J.H.G. Jonkman, J.F. Bohle.
Determination of pilocarpine, isopilocarpine, pilocarpic acid and isopilocarpic acid in human plasma and urine by high-performance liquid chromatography with tandem mass-spectrometric detection.
Journal of Chromatography B, 708(1998)103-112.
262. N.C. van de Merbel, A.P. Tinke, W.D. van Dongen, B. Oosterhuis, J.H.G. Jonkman, Ph. Ladure, C. Puozzo.
Validated method for the determination of idazoxan in human plasma by liquid chromatography with tandem mass-spectrometric detection.
Journal of Chromatography B, 708(1998)113-120.
263. P.A.M. Peeters, J.J. van Lier, N. van de Merbel, B. Oosterhuis, J. Wieling, J.H.G. Jonkman, K. Klessing, A. Biber.
Pharmacokinetics of [¹⁴C]-labelled losigamone and enantiomers after oral administration to healthy subjects.
European Journal of Drug Metabolism and Pharmacokinetics, 23(1998)45-53.
264. J. Wemer, B. Oosterhuis, B. Wilffert and J.H.G. Jonkman.
Surrogaat eindpunten in klinisch farmacologisch onderzoek.
Conceptuur 17(1998)4-6.
265. M.G.C. Hendriks, P. Dogterom, J.T. Ebels, B. Oosterhuis, L.R. Geertsema, T. Hulot, G. Bianchetti, J.H.G. Jonkman.
A study comparing biopharmaceutic characteristics of four once daily controlled release diltiazem preparations.
Fundamental Clinical Pharmacology 12(1998)559-565.
266. E.J. Seaber, R.W. Peck, D.A. Smith, J. Allanson, N.R. Hefting, J.J. van Lier, F.A.E. Sollie, J. Wemer, J.H.G. Jonkman.
The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers.
British Journal of Clinical Pharmacology 46(1998)433-439.
267. J. Hempenius, J. Wieling, J.P.G. Brakenhoff, F.A. Maris, J.H.G. Jonkman.
High-throughput solid-phase extraction for the determination of cimetidine in human plasma.
Journal of Chromatography B, 714(1998)361-368.
268. T.H.M. Heijenbrok-van Herpen, D.J. Touw, C.J. Deerenberg-Veenstra, D. Compas, R.O.B. Gans, W.J. Tamminga, J. Wemer, A.C. van Loenen
Genetic polymorphism. Phenotyping three CYP iso-enzymes, a study to validate a phenotyping procedure with a cocktail of markers.
Ziekenhuisfarmacie 14(1998)135-143.

269. J.H.G. Jonkman
De vermijding. Opsporing en preventie van wetenschappelijk wangedrag
Medisch Journaal, jaargang 27, no. 4 (1998) 138 – 142.
270. S. Snel, J.A. Jansen, P.C. Pedersen, J.H.G. Jonkman, P.N. van Heiningen
Tiagabine a novel antiepileptic agent: lack of pharmacokinetic interaction with digoxin.
European Journal Clinical Pharmacology, 54(1998)355-357

1999

271. M.M. Young, L. Squassante, J. Wemer, S.P. van Marle, P. Dogterom, J.H.G. Jonkman
Troglitazone has no effect on red cell mass or other erythropoietic parameters
European Journal Clinical Pharmacology, 55(1999)101-104
272. A. Le Liboux, J.P. Cachia, S. Kirkesseli, J.Y. Gautier, C. Guimart, G. Montay, P.A. Peeters,
E. Groen, J.H.G. Jonkman, J. Wemer
A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose
administration in healthy elderly and young volunteers.
Journal Clinical Pharmacology, 39(1999)480-486
273. W.J. Tamminga, J. Wemer, B. Oosterhuis, J. Wieling, B. Wilffert, L.F. de Leij, R.A. de Zeeuw,
J.H.G. Jonkman
CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications
for oral contraceptive-related gender differences.
European Journal Clinical Pharmacology, 55(1999)177-184
274. S. Selim, F.J. Preiss, K.L. Gabriel, J.H.G. Jonkman, T.G. Osimitz
Absorption and mass balance of piperonyl butoxide following an 8-h dermal exposure in human
volunteers
Toxicol Lett., 107(1999)207-217
275. C. Weber, R. Schmitt, H. Birnboeck, G. Hopfengartner, H. Eggers, J. Meyer, S. van Marle,
H.W. Vischer, J.H.G. Jonkman
Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor
antagonist, in healthy male volunteers.
Journal Clinical Pharmacology, 39(1999)703-714
276. P.A. Peeters, H.J. Crijns, W.J. Tamminga, J.H.G. Jonkman, J.P. Dickinson, J. Necciari
Clopidogrel, a novel antiplatelet, and digoxin: absence of pharmacodynamic and
pharmacokinetic interaction.
Semin Thromb Hemost, 25(1999)51-54
277. P.N.M. van Heiningen, V. Hatorp, K. Kramer Nielsen, K.T. Hansen, J.J. de Lier, N.C. Van
Merbel, B. Oosterhuis, J.H.G. Jonkman
Absorption, metabolism and excretion of a single oral dose of ¹⁴C-repaglinide during
repaglinide multiple dosing
European Journal Clinical Pharmacology, 55(1999)521-525

278. A.A. van Vliet, J. Wemer, B. Wilfert, J.W.P. de Vroedt and J.H.G. Jonkman
Informed consent in healthy volunteers: whom does it protect?
Good Clinical Practice Journal, 6 (1999) 23-26

2000

279. J. Wieling, W.J. Tamminga, E.P. Sakiman, B. Oosterhuis, J. Wemer and J.H.G. Jonkman
Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening
Therapeutic Drug Monitoring 22 (2000) 486-496
280. F.M. Lagerwerf, W.D. van Dongen, R.J.J.M. Steenvoorden, M. Honing and J.H.G. Jonkman
Exploring the boundaries of bioanalytical quantitative LC-MS-MS
Trends in Analytical Chemistry 19 (2000) 418-427

2001

281. W.J. Tamminga, J. Wemer, B. Oosterhuis, J. Wieling, D.J. Touw, R.A. de Zeeuw, L.F.M.H. de Leij and J.H.G. Jonkman
Mephenytoin as a probe for CYP2C19 phenotyping: effect of sample storage, intra-individual reproducibility and occurrence of adverse events
British Journal of Clinical Pharmacology 51 (2001) 471-474
282. W.J. Tamminga, J. Wemer, B. Oosterhuis, J. Wieling, J.P.G. Brakenhoff, M.G.F. Gerrits, R.A. de Zeeuw, L.F.M.H. de Leij and J.H.G. Jonkman
An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19
European Journal of Clinical Pharmacology 57 (2001) 143-146
283. W.J. Tamminga, J. Wemer, B. Oosterhuis, R.A. de Zeeuw, L.F.M.H. de Leij and J.H.G. Jonkman
The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers.
European Journal of Clinical Pharmacology 57 (2001) 717-722
284. W.J. Tamminga, J. Wemer, B. Oosterhuis, A. de Boer, S. Vranckx, B.F.H. Drenth, R.A. de Zeeuw and J.H.G. Jonkman
The pharmacotherapy of hospitalised psychiatric patients related to CYP2D6 genotypes
Pharmacology & Toxicology 89, Suppl. 1 (2001) 106
285. J.H.G. Jonkman
Genen: hun rol in geneesmiddelenontwikkeling en –gebruik
Foliolum II 5 (2001) 27-29

2002

286. J.H.G. Jonkman
Geneesmiddelenonderzoek en wetenschappelijke integriteit
Conceptuur 31 (2002) 16-18

2003

287. W.J. Tamminga, J. Wemer, B. Oosterhuis, A. de Boer, S. Vranckx, B.F.H. Drenth, R.A. de Zeeuw, L.F.M.H. de Leij, J.H.G. Jonkman
Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study
European Journal of Clinical Pharmacology 59 (2003) 57-64

2004

288. J.H.G. Jonkman
Geneesmiddelenonderzoek: recente ontwikkelingen
Patient Care 31 (2004) 731-736
289. J.H.G. Jonkman
Clinical Trials Directive: Implementatie verder vertraagd
Conceptuur 41 (2004) 12-14

2005

290. J.H.G. Jonkman
Nog steeds geen nieuwe WMO
Conceptuur 42 (2005) 24
291. J.H.G. Jonkman
Eindelijk nieuwe wet klinisch onderzoek
Conceptuur 45 (2005) 16
292. J.H.G. Jonkman
De basis van een weloverwogen oordeel.
Pharmaceutisch Weekblad 18 (2005) 611-612

2006

293. J.H.G. Jonkman
Geneesmiddelenonderzoek: hoe gaat dat?
Foliolum 20 (2006) 15-19

2008

294. J.H.G. Jonkman
Good Clinical Practice: Noodzaak examinering en certificering
Conceptuur 54 (2008) 20
295. H.J. Lambers Heerspink, F.J.C. Cuperus and J.H.G. Jonkman
Nieuwe Europese wetgeving voor geneesmiddelenstudies in kinderen
Conceptuur 57 (2008) 24-25

3. BOOKS

1984

1. J.H.G. Jonkman, J.W. Jenne and F.E.R. Simons.
Sustained release theophylline in the treatment of chronic reversible airways obstruction.
Excerpta Medica, Amsterdam, 1984, ISBN 902196197.

1994

2. J.H.G. Jonkman en J.H. Furnée.
Het Noorder Sanatorium te Zuidlaren: geschiedenis en architectuur van een psychiatrisch monument.
Pharma Bio-Research International B.V., Zuidlaren, 1994, ISBN 90-9007318-3.

1998

3. Prof. Dr. J.H.G. Jonkman.
Integriteit van biomedisch en farmaceutisch onderzoek
Modern kwaliteitsmanagement in geneesmiddelenonderzoek.
Pharma Bio-Research International B.V., Zuidlaren, 1998, ISBN 90-2323387-5.

4. LECTURES

1974

1. Farmacochemie congres dag (Sectie Farmacochemie der K.N.C.V. en K.N.M.P.), Utrecht, The Netherlands, March 1974. De kwantitatieve analyse van thiazinamium methylsulfaat (Multergan®) in lichaamsvloeistoffen.
2. British Pharmaceutical Conference, Nottingham, UK, September 1974 (+ J. Wijsbeek, S. Hollenbeek Brouwer-de Boer, R.A. de Zeeuw).
Bioavailability of the quaternary ammonium compound thiazinamium methylsulphate (Multergan®) after oral and intramuscular administration.

1975

3. 35th International Pharmaceutical Conference (F.I.P.-congress), Dublin, Ireland, September 1975 (+ J. Wijsbeek, S. Hollenbeek Brouwer-de Boer, R.A. de Zeeuw, L.E. van Bork, N.G.M. Orie).
Bioavailability, metabolism and excretion of the quaternary ammonium compound thiazinamium methylsulphate after different routes of administration.

1976

4. Farmacochemie congres dag (Sectie Farmacochemie der K.N.C.V. en K.N.M.P.), The Hague, The Netherlands, April 1976 (+ J. Wijsbeek, R.A. de Zeeuw, L.E. van Bork, N.G.M. Orie).
De biologische beschikbaarheid van de kwaternaire ammonium verbinding thiazinamium methylsulfaat (Multergan®) na verschillende wijzen van toediening bij de mens.
5. Federatieve Vergadering van Medisch-Biologische Verenigingen, Amsterdam, The Netherlands, April 1976 (+ J. Wijsbeek, R.A. de Zeeuw, L.E. van Bork, N.G.M. Orie).
Determination of bioavailability and pharmacokinetic parameters in man, using pharmacological data.
6. Federatieve Vergadering van Medisch-Biologische Verenigingen, Amsterdam, The Netherlands, April 1976 (+ H.G.M. Westenberg, J. Wijsbeek, E. van der Kleijn).
Pharmacokinetics and metabolism of the quaternary ammonium compound thiazinamium methylsulphate (Multergan®) in dogs.
- 6A. Federatieve Vergadering van Medisch-Biologische Verenigingen, Amsterdam, The Netherlands, April 1976 (+ H.G.M. Westenberg, E.M. Wirix, E. van der Kleijn).
Pharmacokinetics of carbamazepine in animals.
7. British Pharmaceutical Conference, St. Andrews, UK, September 1976 (+ L.E. van Bork, J. Wijsbeek, R.A. de Zeeuw, N.G.M. Orie, H.L.M. Cox).
'First pass effect' after rectal administration of thiazinamium methylsulphate.

1977

8. Conference on Autoradiography, Uppsala, Sweden, May 1977 (+ H.G.M. Westenberg, E. van der Kleijn).
A comparison of the distribution of promethazine and its quaternary analogue in mice and monkey.
9. 37th International Pharmaceutical Conference (F.I.P.-congress), The Hague, The Netherlands, September 1977 (+ L.E. van Bork, J. Wijsbeek, A.S. Bolhuis-de Vries, R.A. de Zeeuw, N.G.M. Orie, H.L.M. Cox).
Comparison of the 'first pass effect' after oral and rectal administration of thiazinamium methylsulphate in man.

1978

- 9A. Second PHORUM meeting, Brandon, Near Coventry, United Kingdom, April 1978.
Enhancement of quaternary ammonium ion absorption.

1979

10. International Theophylline Symposium, London, UK, May 1979 (+ W.Chr. Berg, R.A. de Zeeuw, N.G.M. Orie, R. Schoenmaker).
The absolute bioavailability of microcrystalline theophylline.
11. University of California, San Francisco, USA, School of Pharmacy, Department of Pharmacy, June 1979.
Bioanalysis of the quaternary ammonium compound thiazinamium methylsulphate.
12. University of California, San Francisco, USA, School of Pharmacy, October 1979.
Pharmacokinetics and metabolism of thiazinamium methylsulphate.
13. University of Iowa, Iowa City, USA, School of Pharmacy, November 1979.
Bioanalysis and clinical pharmacokinetics of some anti-asthmatic drugs.
14. University of Cincinnati, Cincinnati, Ohio, USA, School of Pharmacy, November 1979.
Bioanalysis and clinical pharmacokinetics of some anti-histaminic drugs.
15. Symposium 'The serum concentration of drugs' organized by de Nederlandse Vereniging van Ziekenhuisapothekers, Amsterdam, The Netherlands, December 1979 (+ A.M. Soeterboek).
Bioanalysis of theophylline.

1980

16. ALZA Corp., Palo Alto, California, USA, September 1980.
Formation of ion pairs and drug absorption.
17. United States Government, Food and Drug Administration, Division of Biopharmaceutics, Washington D.C., USA, October 1980.
Correlation between 'in vitro' dissolution and 'in vivo' disposition of two new sustained release theophylline preparations.

1981

18. First European Congress of Biopharmaceutics and Pharmacokinetics, Clermont Ferrand, France, April 1981 (+ W.Chr. Berg, G.H. Koëter, N. Grimberg, R. Schoenmaker, R.A. de Zeeuw, K. de Vries).
The correlation between 'in vitro' dissolution and 'in vivo' disposition of sustained release theophylline tablets.
19. Federatieve Vergadering van Medisch-Biologische Verenigingen, Utrecht, The Netherlands, April 1981, Microsymposium 'Bronchus constriction: pharmacological aspects' (+ W.Chr. Berg, G.H. Koëter, R. Schoenmaker, R.A. de Zeeuw, K. de Vries).
Serum level profiles of theophylline after administration of sustained release dosage forms.
20. 4th International Symposium 'Methods in Clinical Pharmacology - Theophylline and other Methylxanthines', Frankfurt am Main, Germany, May 1981 (+ W.Chr. Berg, R. Schoenmaker).
Irreproducible serum concentration-time profiles after intake of a new sustained release theophylline tablet.
21. 4th International Symposium 'Methods in Clinical Pharmacology - Theophylline and other Methylxanthines', Frankfurt am Main, Germany, May 1981 (+ K.T. Muir, D.S. Tang, S. Riegelman).
Selective quantitative determination of methylxanthines and methyl uric acids in urine.
22. 41st International Congress of Pharmaceutical Sciences (F.I.P.-congress), Vienna, Austria, September 1981 (+ J.P. Franke, R. Schoenmaker, R.A. de Zeeuw).
Stability of theophylline in serum during storage at different temperatures.
23. 41st International Congress of Pharmaceutical Sciences (F.I.P.-congress), Vienna, Austria, September 1981 (+ W.Chr. Berg, R. Schoenmaker, R.A. de Zeeuw).
Dissolution and absorption profiles after rapidly dissolving and sustained release theophylline tablets.
24. Symposium ter gelegenheid van het 25-jarig bestaan van het Laboratorium der Nederlandse Apothekers, The Hague, The Netherlands, September 1981.
De betekenis van het L.N.A. voor de praktijkapotheker.

1982

25. Winter-congres van de Koninklijke Nederlandse Chemische Vereniging, Sectie Analytische Chemie, Amsterdam, The Netherlands, January 1982.
Bioanalyse van anti-asthmatica.
26. The Sidney Riegelman Memorial Symposium 'Pharmacokinetics: a modern view', San Francisco, USA, April 1982 (+ D.D.S. Tang-Liu, K.T. Muir, M. Kunitani, S. Riegelman).
An automated HPLC-assay for simultaneous quantitation of fourteen methylated xanthines and uric acids in urine.

27. Conference on 'Sustained Release Theophylline', Amsterdam, The Netherlands, June 1982 (+ W.Chr. Berg, R.A. de Zeeuw).
Dissolution models involving a pH-change: their correlation with absorption of theophylline from sustained release tablets.
28. University of Florida, Gainesville, USA, College of Pharmacy, August 1982.
Biopharmaceutics of theophylline.
- 28A. Fifth Meeting of the Working Group on Respiratory Clinical Pharmacology, Frankfurt, Germany, March 1982 (+ L.E. van Bork, J.E. Greving, N.G.M. Orie, R. Peset, H. de Vries and R.A. de Zeeuw).
Pharmacodynamics of thiazinamium methylsulphate and oxyphenonium bromide and the difference in effect between aerosol of oxyphenonium bromide or ipratropium bromide and a metered aerosol of oxyphenonium bromide.
- 28B. Fifth Meeting of the Working Group on Respiratory Clinical Pharmacology, Frankfurt, Germany, March 1982 (+ J.E. Greving, L.E. van Bork, N.G.M. Orie and R.A. de Zeeuw).
Pharmacokinetics of thiazinamium methylsulphate and oxyphenonium bromide in relation to its pharmacodynamics.

1983

29. Symposium 'Theofylline bij CARA', Almere, The Netherlands, April 1983.
Biofarmaceutische en farmacokinetische aspecten van theofylline therapie.
30. Asthma Symposium, Lund, Sweden, May 1983.
Factors influencing absorption of sustained release theophylline.
31. 43rd International Congress of Pharmaceutical Sciences (F.I.P.-congress), Montreux, Switzerland, September 1983 (+ L.P. Balant, W.J.V. van der Boon, R. Schoenmaker, A. Holtkamp).
Chronopharmacokinetics of theophylline in man.
32. Second conference on 'Sustained Release Theophylline', Mont Ste Marie, Ottawa, Canada, September 1983.
Biopharmaceutical and pharmacokinetic drug interactions with theophylline.
33. Symposium 'Chronofarmacologie, de invloed van biologische rhythmten op de medicatie', Ammerzoden, The Netherlands, November 1983.
Chronofarmacokinetiek van theofylline.

1984

34. Symposium 'Progressi in pneumologia: la teofillina ritardo', Palermo, Italy, March 1984.
In vitro dissolution tests and their relation to in vivo absorption from sustained release theophylline.
35. 'Biological Rhythms and Medications', First International Montreux Conference on Chronopharmacology, Montreux, Switzerland, March 1984 (+ M.H. Smolensky).
Chronopharmacology of theophylline, with special reference to age.

36. Symposium 'Sustained release theophyllines: factors influencing disposition and therapeutic effect', Cologne, Germany, April 1984.
In vitro modelling and its relation to in vivo absorption.
37. Symposium 'Sustained release theophyllines: factors influencing disposition and therapeutic effect', Cologne, Germany, April 1984 (+ W.J.V. van der Boon).
Drugs influencing theophylline disposition.
38. Congres Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Utrecht, The Netherlands, May 1984.
Het effect van cefaclor op de klinische farmacokinetiek van theofylline.
39. Second European Congress of Biopharmaceutics and Pharmacokinetics, Salamanca, Spain, April 1984 (+ W.J.V. van der Boon, A. Holtkamp, J. Hempenius).
The influence of cefaclor on the clinical pharmacokinetics of theophylline.
40. Second European Congress of Biopharmaceutics and Pharmacokinetics, Salamanca, Spain, April 1984 (+ W.J.V. van der Boon, R. Schoenmaker, A. Holtkamp).
The influence of antacid on theophylline absorption from two sustained release preparations.
41. Second European Congress of Biopharmaceutics and Pharmacokinetics, Salamanca, Spain, April 1984 (+ L.P. Balant, W.J.V. van der Boon, R. Schoenmaker, A. Holtkamp).
Circadian variation in theophylline elimination.
- 41A. Congres Koninklijke Nederlandse Chemische Vereniging, Sectie Analytische Chemie, Werkgroep Farmaceutische en Bio-Medische Analyse (FABIAN), Utrecht, The Netherlands, November 1984 (+ R. Schoenmaker, J. Hempenius).
Bioanalysis of amoxicillin by ion pair column extraction and reversed-phase ion pair HPLC.
- 41B. Congres Koninklijke Nederlandse Chemische Vereniging, Sectie Analytische Chemie, Werkgroep Farmaceutische en Bio-Medische Analyse (FABIAN), Utrecht, The Netherlands, November 1984 (+ J. Hempenius, A. Holtkamp).
Rapid analysis of ibuprofen in plasma by column extraction and reversed-phase HPLC.

1985

42. Anti-asthma Xanthines and Adenosine Symposium, Copenhagen, Denmark, February 1985 (+ O. Borga, W.J.V. van der Boon, G. Grasmeijer, I. Hakansson).
Pharmacokinetics of enprophylline: relationship to age, sex, smoking habits and creatinine clearance.
43. Anti-asthma Xanthines and Adenosine Symposium, Copenhagen, Denmark, February 1985 (+ J. Kraan, I. Hakansson, G.H. Koëter, H.J. Sluiter, R.A. de Zeeuw).
Enprophylline and theophylline pharmacokinetics compared in patients with impaired hepatic or renal function.
44. Seminarium voor Kindergeneeskunde: 'Ademhalings-aandoeningen bij Kinderen', Antwerp, Belgium, February 1985.
Orale theophylline therapie.

45. Congres Koninklijke Nederlandse Chemische Vereniging, Sectie Analytische Chemie, Werkgroep Farmaceutische en Biomedische Analyse (FABIAN), Amsterdam, The Netherlands, March 1985. Voorbeelden van het gebruik van chromatografische technieken bij het oplossen van farmaceutisch-biomedische problemen.
46. 'Up-date on Theophylline' (F.D.A. sponsored symposium), Washington, USA, September 1985. Pharmacokinetic drug interactions with theophylline.
47. Fourth Congress of the European Society of Pneumology, Milan, Italy, September 1985 (+ W.J.V. van der Boon, G. Grasmeijer, A. Holland). No influence of breakfast on the disposition of the 24-hour sustained release theophylline capsule Dilatrane® A.P. 400 mg.

1986

48. 'Biological Rhythms and Medications', Second International Montreux Conference on Chronopharmacology, Montreux, Switzerland, March 1986. The role of food intake on day-night differences in theophylline absorption.
49. Third World Conference on Clinical Pharmacology & Therapeutics, Stockholm, Sweden, July 1986 (+ R.A. de Zeeuw, J.P. Yska, B.E. Cabana). Interindividual differences in dextromethorphan kinetics in man.
50. Third World Conference on Clinical Pharmacology & Therapeutics, Stockholm, Sweden, July 1986 (+ R.A. de Zeeuw, J. Wiechers, J. Oren, R.D.T. Thompson). Percutaneous absorption and elimination of Azone® in man.
51. 'Sustained Release Theophylline for Once-a-Day Dosing', Bassenthwaite, England, September 1986. A comparison of plasma profiles after Theo-Dur⁷ twice daily and theophylline K-1B capsules (Riker Laboratories) once daily in volunteers.
52. Conference on Transdermal Drug Delivery Systems, Neu-Ulm, Germany, December 1986 (+ J. Wiechers, R.A. de Zeeuw, B.F.H. Drenth). Percutaneous absorption and elimination of Azone⁷ in humans.

1987

53. Third European Congress of Biopharmaceutics and Pharmacokinetics, Freiburg, Germany, April 1987 (+ W.J.V. van der Boon, G. Grasmeijer). Intra-subject variability of theophylline pharmacokinetics after intravenous administration.
54. Third European Congress of Biopharmaceutics and Pharmacokinetics, Freiburg, Germany, April 1987 (+ G. Bianchetti, J.F. Thiercelin, V. Ascalone, P. Guinebault, J.P. Thenot). Pharmacokinetic profile of alpidem, a new anxiolytic, in healthy volunteers.

55. Third European Congress of Biopharmaceutics and Pharmacokinetics, Freiburg, Germany, April 1987 (+ Ph. Guillet, V. Ascalone, G. Bianchetti, P. Padovani, J.F. Thiercelin, E. Bercoff, A. Crema, A. Meyrier).
Influence of physiological and pathological factors on the pharmacokinetics of alpidem, a new imidazopyridine anxiolytic agent.
56. 22nd Annual Meeting of the Societas Europaea Physiologiae Clinicae Respiratoriae (S.E.P.C.R.), Antwerp, Belgium, June 1987.
Theophylline metabolism and its interactions.
57. Second National Meeting of the American Association of Pharmaceutical Scientists (A.A.P.S.), Boston, USA, June 1987 (+ J.W. Wiechers, B.F.H. Drenth, R.A. de Zeeuw and R. Vaidyanathan).
In vivo percutaneous absorption and elimination of ¹⁴C-labeled Azone in humans.
58. 47th International Congress of Pharmaceutical Sciences (F.I.P.-congress), Amsterdam, The Netherlands, September 1987 (+ A.S.C. Wymenga, W.J.V. van der Boon, J.K. Beugelink and B. Oosterhuis).
Influenza vaccination does not alter theophylline pharmacokinetics as studied by UV-spectrophotometry, HPLC and EMIT⁷ assay methods.
59. 47th International Congress of Pharmaceutical Sciences (F.I.P.-congress), Amsterdam, The Netherlands, September 1987 (+ B. Oosterhuis, F.A. Kerkhof, J.P. Yska and G. Grasmeijer).
Time profile of metoprolol plasma concentration and effect on exercise induced heart rate during multiple dosing with different sustained release preparations in extensive and poor metabolizers.
60. 47th International Congress of Pharmaceutical Sciences (F.I.P.-congress), Amsterdam, The Netherlands, September 1987 (+ R.A. de Zeeuw and B.E. Cabana).
Large differences in dextromethorphan steady state levels due to polymorphic metabolism.
61. Conference on Novel Drug Delivery Systems, Neu-Ulm, Germany, September 1987 (+ J.W. Wiechers, B.F.H. Drenth and R.A. de Zeeuw).
The percutaneous absorption and excretion of azone and triamcinolone acetonide from a cream under single and multiple dosing conditions.
62. Symposium 'New Developments in Mechanisms and Treatment of Bronchial Obstruction', Santiago de Compostela, Spain, October 1987.
Pharmacokinetic aspects of bronchodilator therapy.
63. Symposium 'New Developments in Mechanisms and Treatment of Bronchial Obstruction', Santiago de Compostela, Spain, October 1987 (+ W.J.V. van der Boon, G. Grasmeijer).
A comparison of the steady state plasma concentrations of theophylline from Theolin® Retard and Pharphylline®.
64. Symposium 'New Developments in Mechanisms and Treatment of Bronchial Obstruction', Santiago de Compostela, Spain, October 1987 (+ O. Börga, W.J.V. van der Boon, G. Grasmeijer, I. Ekman).
Pharmacokinetics of enprophylline: relationship to age, sex, smoking habits, oral contraceptive use and creatinine clearance.

65. Symposium 'New Developments in Mechanisms and Treatment of Bronchial Obstruction', Santiago de Compostela, Spain, October 1987 (+ J. Kraan, G.H. Koëter, Th.W. van der Mark, M. Boorsma, J. Kukler, H.J. Sluiter, K. de Vries).
Theophylline and enprophylline partially inhibits methacholine-induced bronchoconstriction in asthmatic subjects.
66. Congres Koninklijke Nederlandse Chemische Vereniging, Sectie Analytische Chemie, Werkgroep Farmaceutische en Bio-Medische Analyse (FABIAN), Weesp, The Netherlands, November 1987 (+ O.E. de Noord, J. Hempenius, P.M.J. Coenegracht, D.A. Doornbos).
Development for robotised optimization of sample pre-treatment techniques for chromatographic analysis of biological matrices.

1988

67. 'Biological Rhythms and Medications', Third International Conference of Chrono-pharmacology, Nice, France, March 1988 (+ A. Reinberg, B. Oosterhuis, O.E. de Noord, F.A. Kerkhof, Y. Motohashi, F. Lévi, F. Carandente).
Dosing-time and sex-related differences in the pharmacokinetics of cefodizime.
68. International Conference on Pharmaceutical Sciences and Clinical Pharmacology, Jerusalem, Israël, June 1988 (+ J.W. Wiechers, B.F.H. Drenth, R.A. de Zeeuw).
Effect of azone on the percutaneous absorption of triamcinolone acetonide from a cream in humans.
69. International Conference on Pharmaceutical Sciences and Clinical Pharmacology, Jerusalem, Israel, June 1988 (+ J.W. Wiechers, B.F.H. Drenth, R.A. de Zeeuw).
Percutaneous absorption and excretion of azone after dosing as such and in a triamcinolone acetonide cream.
70. Sixth International Symposium on Laboratory Robots, Boston, USA, October 1988 (+ O.E. de Noord, J. Hempenius, P.M.J. Coenegracht and D.A. Doornbos).
Development of robotised optimization of sample pretreatment techniques for chromatographic analysis of biological samples.
71. National Conference on Omeprazole-1, Maastricht, The Netherlands, November 1988 (+ B. Oosterhuis).
Omeprazole, pharmacology and interactions.
72. Congres Koninklijke Nederlandse Chemische Vereniging, Sectie Analytische Chemie, Werkgroep Farmaceutische en Bio-Medische Analyse (FABIAN), Groningen, The Netherlands, November 1988 (+ H.J. Jeuring).
Development of robotised sample preparation techniques in bioanalysis.

1989

73. National Conference on Omeprazole-2, Scheveningen, The Netherlands, April 1989 (+ B. Oosterhuis).
Omeprazole, pharmacology and interactions.

74. Third International Symposium on Drug Analysis, Antwerp, Belgium, May 1989 (+ J. Wieling, J. Hempenius, H.J. Jeuring, P.M.J. Coenegracht and D.A. Doornbos).
Development of robotised guarded sample preparation techniques for chromatographic analysis of biological matrices.
75. Fourth World Conference on Clinical Pharmacology and Therapeutics, Mannheim-Heidelberg, Germany, 1989 (+ D.N. Duong, P.B.M. Zuiderwijk, R.G.L. van Tol and P.J.G. Cornelissen).
Pharmacodynamics and tolerability of ULFS-49, a new specific bradycardic agent.
76. Fourth World Conference on Clinical Pharmacology and Therapeutics, Mannheim-Heidelberg, Germany, 1989 (+ B. Oosterhuis, G. Nemisz, P.J.G. Cornelissen, P.B.M. Zuiderwijk, H.J. Jeuring, C.A.P.F. Su and R.G.L. van Tol).
Uricosuric effect of ambroxol.
77. Fourth World Conference on Clinical Pharmacology and Therapeutics, Mannheim-Heidelberg, Germany, 1989 (+ F.A.E. Sollie, J. Dingemans, H. Staudinger and V.W. Steinijans).
Investigation of the influence of caffeine on the pharmacokinetics of theophylline.
78. Congres Koninklijke Nederlandse Chemische Vereniging, Sectie Analytische Chemie, Werkgroep Farmaceutische en Bio-Medische Analyse (FABIAN), Oss, The Netherlands, November 1989 (+ J. Hempenius and C.K. Mensink).
Determination of debrisoquine and 4-OH-debrisoquine in human urine by reversed phase high performance liquid chromatography and fluorescence detection.
79. Congres Koninklijke Nederlandse Chemische Vereniging, Sectie Analytische Chemie, Werkgroep Farmaceutische en Bio-Medische Analyse (FABIAN), Oss, The Netherlands, November 1989 (+ J. Wieling, J. Hempenius, P.M.J. Coenegracht, H.J. Jeuring and D.A. Doornbos).
Introduction of mixture experimental design in the optimization of liquid extraction of drugs from biological matrices.

1990

80. Fourth European Congress of Biopharmaceutics and Pharmacokinetics, Geneva, Switzerland, April 1990 (+ W. Roth, E. Bauer, P.J.G. Cornelissen, R.G.L. van Tol and P.B.M. Zuiderwijk).
Pharmacokinetics of UL-FS 49 Cl, a new specific heart rate lowering agent in healthy volunteers.
81. International Symposium on Measurement and Kinetics of 'In Vivo' Drug Effects (IUPHAR Satellite symposium) Noordwijk, The Netherlands, June 1990 (+ B. Oosterhuis, P.B.M. Zuiderwijk, F.A.E. Sollie and H.W. Visscher).
Metoprolol pharmacokinetics and effect on exercise heart rate in steady state during multiple dosing with controlled release formulations: multiple-unit formulation compared with matrix formulation and placebo.
82. Euroanalysis VII, Vienna, Austria, August 1990 (+ J. Wieling, P.M.J. Coenegracht, C.A.A. Duineveld, C.K. Mensink and D.A. Doornbos).
Combination of mixture and factorial variables in one experimental design to investigate interactions between extraction liquid composition and extraction conditions.

83. Congres Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Utrecht, The Netherlands, October 1990 (+ P.N.M. van Heiningen, B. Oosterhuis, H. de Bruin and J.A.R.J. Hulsman).
Pharmacokinetics of the antiepileptic drug oxcarbazepine in relation to age.
84. Course on 'Controlled Release Products - Recommendation in Support of EC-Guidelines', organized by Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik (International Association for Pharmaceutical Technology), Cologne, Germany, October 1990 (+ B. Oosterhuis).
Single dose versus multiple dose administration.
85. Congres Koninklijke Nederlandse Chemische Vereniging, Sectie Analytische Chemie, Werkgroep Farmaceutische en Bio-Medische Analyse (FABIAN), Eindhoven, The Netherlands, November 1990 (+ J. Wieling, J. Schepers, J. Hempenius and C.K. Mensink).
Reversed-phase high-performance liquid chromatographic separation of 12 sulphonamides using mixture design statistical mobile phase optimization and multi criteria decision making.

1991

86. Congres Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Utrecht, The Netherlands, April 1991 (+ O.R. Leeuwenkamp, H.W. Visscher, E. Louwerens and K.J. van Aubel).
A comparative study on the steady-state pharmacokinetics of controlled-release and immediate-release diltiazem tablet preparations.
87. International Boerhave Course on 'Drug-drug interactions and drug-food interactions', Leiden, The Netherlands, May 1991 (+ B. Oosterhuis).
Food and bioavailability and bioequivalence studies.
88. Third European Congress on Obesity, Nice, France, May 1991 (+ C. Güzelhan, H.J.M.J. Crijns, P.A.M. Peeters and D. Hartmann).
Pharmacological activity (inhibition of fat absorption) and tolerability in healthy volunteers of tetrahydrolipstatin (THL) - specific lipase inhibitor.
89. Fifteenth International Symposium on Column Liquid Chromatography ('HPLC '91'), Basel, Switzerland, June 1991 (+ J. Wieling, P.M.J. Coenegracht, C.K. Mensink and D.A. Doornbos).
Monte Carlo simulation of improvement of assay methods with liquid-liquid extraction prior to HPLC: selection of robust combinations of extraction liquid composition and internal standard.
90. Thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, September/October 1991 (+ G. Montay, R. Bruno, J.C. Vergniol, J. Rey, A. Frydman, P.A.M. Peeters and I. Dhont).
Pharmacokinetics of Sparfloxacin after Repeated Administration in Healthy Volunteers.
- 90A. Congres Koninklijke Nederlandse Chemische Vereniging, Sectie Analytische Chemie, Werkgroep Farmaceutische en Biomedische Analyse (FABIAN), Leiden, The Netherlands, November 1991 (+ J. Wieling, A.N. Grimberg and C.K. Mensink).
The effect of the experimental error of analytical assay methods on the determination of pharmacokinetic parameters: a Monte Carlo simulation.

1992

91. Congres Belgische en Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Gent, Belgium, April 1992 (+ M.-L. Huang, A. van Peer, R. Woestenborgh and J. Heykants). Pharmacokinetics of risperidone in dextromethorphan-phenotyped healthy volunteers.
92. BIO-International '92; Conference on Bioavailability, Bioequivalence and Pharmacokinetic Studies, Bad Homburg, Frankfurt, Germany, May 1992 (+ B. Oosterhuis). Significance of the reference product in bioequivalence evaluations: pharmaceutical quality, variability, biopharmaceutical characteristics.
93. 18th World Congress of Dermatology, New York, USA, May 1992 (+ G.A. Roders, H.W. Visscher and P.B.M. Zuiderwijk). A comparative study on adrenal suppressive effect of 0.025% budesonide cream (BUD) and 0.05% betamethasone dipropionate cream (BMP).
94. Fifth World Conference on Clinical Pharmacology and Therapeutics, Yokohama, Japan, July 1992 (+ P.N.M. van Heiningen, B. Oosterhuis, J.J. van Lier, C.K. Mensink, H. de Bruin and I. Castagné). Pharmacokinetics of the anti-ischaemic compound trimetazidine in relation to age.
- 94A. Fifth World Conference on Clinical Pharmacology and Therapeutics, Yokohama, Japan, July 1992 (+ J.F. Thiercelin, P.B.M. Zuiderwijk, P.A.M. Peeters, C.K. Mensink, J. Neccari and H. de Bruin). Tolerance and pharmacokinetics of tiludronate after multiple dose administration of 200, 400, 600 and 800 mg to healthy volunteers.
95. Stability Research Group Symposium, Utrecht, The Netherlands, November 1992 (+ B. Oosterhuis). Bioanalyse in de context van biofarmaceutisch onderzoek: kwalitatieve en kwantitatieve randvoorwaarden.

1993

96. Spring Meeting Groningen Institute for Drug Studies (GIDS), Groningen, The Netherlands, March 1993 (+ J. Wieling, A.N. Grimberg and C.K. Mensink). The effect of the experimental error of analytical assay methods on the determination of pharmacokinetic parameters: a Monte Carlo simulation.
97. Mededelingendag Belgische en Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Utrecht, The Netherlands, April 1993 (+ P.N.M. van Heiningen, H.R. Schwietert, J.M. Kortboyer, F.A.E. Sollie, C. Piraupe and P. Desché). Comparison of the pharmacokinetics of trimetazidine in elderly and young volunteers during multiple dose administration of a new sustained release formulation.
98. Fifth European Congress of Biopharmaceutics and Pharmacokinetics, Brussels, Belgium, April 1993 (+ B. Oosterhuis). Pharmacokinetic studies in healthy volunteers in the context of in vitro/in vivo correlations.

99. Fifth European Congress of Biopharmaceutics and Pharmacokinetics, Brussels, Belgium, April 1993 (+ M.-L. Huang, A. van Peer, R. Woestenborghs, J. Heykants, R. de Coster, Z. Zylicz, H.W. Visscher and H.J.G. de Wilde).
Pharmacokinetics of a novel antipsychotic agent risperidone and the prolactin response in volunteers.
100. International course on neurogerontology and psychogeriatrics, La Coruna, Spain, May 1993 (+ K. Wesnes, H. Neuman, H.J.G. de Wilde, M. Malbezin, I. Castagné, D. Guez and H.J.M.J. Crijns).
Preliminary pharmacodynamic effects of a repeated oral administration of 4 dose levels of S12024-2 (Cognitive Enhancer) in 36 healthy elderly volunteers.
101. Congress Dermatology 2000, Vienna, Austria, May 1993 (+ H.W. Visscher, R. Rombout and G.A. Roders).
A comparative study on the adenosuppressive effects of hydrocortisone-17-butyrate (1%) in two different pharmaceutical formulations.
102. Fourteenth Congress of the International Society on Thrombosis and Haemostasis, New York, USA, July 1993 (+ C.R. Jones, R.J. Ambros, H.J. Rapold, B. Steiner, T. Weller, P. van Heiningen, H.J.M.J. Crijns and P. Hadvary).
RO 44-9833: A novel non peptide GPIIb/IIIa antagonist in man.
103. Mededelingendag Belgische en Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Nijmegen, The Netherlands, October 1993 (+ P.A.M. Peeters, B. Oosterhuis, K. Zech, R. Huber and M. Hartmann).
Pantoprazole pharmacokinetics and metabolism after oral and intravenous administration of ¹⁴C-labelled pantoprazole to young healthy male volunteers.
104. Autumn Meeting Groningen Institute for Drug Studies (GIDS), Groningen, The Netherlands, October 1993.
Drug studies in man, with special emphasis on Phase-I studies (State of the art lecture).
105. Autumn Meeting Groningen Institute for Drug Studies (GIDS), Groningen, The Netherlands, October 1993 (+ B. Oosterhuis, Y.S. Tuininga, H.J.G.M. Crijns, A.C.P. Wiesfeld, H. de Bruin, C. Kozma and K.I. Lie).
Pharmacokinetics and haemodynamic effects of restacorin in patients with normal and decreased left ventricular function.
106. Annual Meeting of the American College of Allergy and Immunology, Atlanta, GA, USA, November 1993 (+ M.D. Brannan, H. Groen, P.A.M. Peeters and M.B. Affrime).
Multiple-dose pharmacokinetics of two different sustained-release theophylline preparations.
107. Anselmus Colloquium 'Bioritmen en Farmacotherapie', Utrecht, The Netherlands, November 1993 (+ B. Oosterhuis).
Circadiane ritmen in farmacokinetische processen.
108. Annual Meeting of the American Society of Hematology, St. Louis, MI, USA, December 1993 (+ B. Steiner, C.R. Jones, P.N.M. van Heiningen, R.C. Carroll and W.C. Kouns).
TRAP induced *ex vivo* platelet aggregation might be a useful method to predict anti-thrombotic efficacy.

1994

109. Ninety-fifth Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, New Orleans, USA, March/April 1994 (+ J. Shah, R. Bullingham, J. Curd, R. Taylor and A. Fratis).
PK-PD interaction of ketorolac and furosemide in healthy volunteers in a normovolemic state.
110. Ninety-fifth Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, New Orleans, USA, April 1994 (+ C.A.P.F. Su, P.N.M. van Heiningen, J.J. van Lier, H. de Bruin, K.U. Kirchgaessler and P.J.G. Cornelissen).
Pharmacodynamics of the A II antagonist BIBR0277SE.
111. Mededelingendag Belgische en Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Antwerp, Belgium, April 1994 (+ P.N.M. van Heiningen, J.J. van Lier, H. de Bruin, C.A.P.F. Su, K.U. Kirchgaessler and P.J.G. Cornelissen).
Single dose study on the pharmacodynamics and pharmacokinetics of the angiotensin II antagonist BIBR0277SE.
112. Bio-International '94; Conference on Bioavailability, Bioequivalence and Pharmacokinetic Studies, Munich, Germany, June 1994 (+ J. Wieling and B. Oosterhuis).
Consequences of variation of bioanalytical methods on calculations of pharmacokinetic parameters: simulation and laboratory experience.
113. Fourth International Conference on Alzheimer's Disease and Related Disorders, Minneapolis, Minnesota, USA, July/August, 1994 (+ K. Wesnes, E. Neuman, H.J.G. de Wilde, M. Malbezin, H.J.M.J. Crijns and D. Guez).
Pharmacodynamic effects of repeated oral administration of 4 different doses of S 12024-2 (Cognitive Enhancer) in 36 healthy elderly volunteers.
114. Course 'Good Clinical Practice for Investigational Drug Studies', Post Universitair Onderwijs Ziekenhuisfarmacie (Post-academic Training for Hospital Pharmacists), Utrecht, The Netherlands, September 1994.
The importance of GCP for the medical investigator.
115. European Congress of Epileptology, Oporto, Portugal, September 1994 (+ S. Snel, P.N.M. van Heiningen, J.A. Jansen and H.B. Mengel).
Tiagabine; Evaluation of Risk of Interaction with Cimetidine in Healthy Male Volunteers.
116. Mededelingendag Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Groningen, The Netherlands, October 1994 (+ H. Groen, H.L. Moesker, O.R. Leeuwenkamp, F.A.E. Sollie).
No pharmacokinetic interaction between theophylline and BAY X 1005, a new inhibitor of leukotriene synthesis.
117. Mededelingendag Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Groningen, The Netherlands, October 1994 (+ H.J.G. de Wilde, K. Wesnes, E. Neuman, M. Malbezin, I. Castagné, D. Guez, H.J.M.J. Crijns).
Preliminary pharmacodynamic effects of S 12024-2 (cognitive enhancer) during repeated oral administration at 4 dose levels in 36 healthy elderly volunteers.

1995

118. Mededelingendag Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Tilburg, The Netherlands, March 1995 (+ J.T. Ebels, P. Dogterom, B. Oosterhuis and G. Bianchetti).
Comparison of biopharmaceutic characteristics of four diltiazem controlled release preparations.
119. Mededelingendag Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Tilburg, The Netherlands, March 1995 (+ E.W.J. Groen, H.R. Schwieter, S.P. van Marle, F.A.E. Sollie, J. Wemer, K. Francis and A. Metcalfe).
An evaluation of single dose administration of recombinant human parathyroid hormone (rhPTH(1-84)) in healthy post-menopausal female volunteers.
120. Seminar Rijksinstituut voor Volksgezondheid en Milieuhygiëne (RIVM), Bilthoven, The Netherlands, March 1995 (+ J.H. Proost, B. Oosterhuis and F.A.E. Sollie).
Measures of the rate of absorption in bioequivalence testing.
121. 14th Joint Meeting of the British Endocrine Societies jointly with the European Federation of Endocrine Societies, Warwick, UK, March 1995 (+ A. Verhagen, J.T. Ebels, F.A.E. Sollie and A.A. Dogterom).
Pharmacokinetics and pharmacodynamics of rDNA-hGH after administration by jet-injection: A comparison with conventional needle-injection.
122. 29th Annual Scientific Meeting of the European Society for Clinical Investigation and the Medical Research Society of Great Britain, Cambridge, UK, April 1995 (+ H.J.G. de Wilde, K. Wesnes, E. Neuman, M. Malbezin, I. Castagné, D. Guez, H.J.M.J. Crijns).
Cognitive enhancing effects of S 12024-2 during repeated oral administration at 4 dose levels in 36 healthy elderly volunteers.
- 122A. Fourth International Conference on Endothelin, London, U.K., April 1995 (+ C. Weber, S. Halbeisen, R. Schmitt, H. Birnbock, G. Hopfgartner and S.P. van Marle).
Single dose pharmacokinetics of Bosentan in healthy man.
123. European Conference on Specificity and Variability in Drug Metabolism, Besançon, France, May 1995 (+ B. Oosterhuis, H. Müller-Peltzer, J. Dingemanse, V. Bühler and H. de Bruin).
Pharmacokinetics and Pharmacodynamics of Propafenone in relation with CYP2D6 Pharmacogenetics.
124. HPLC '95, 19th International Symposium on Column Liquid Chromatography and related techniques, Innsbruck, Austria, May/June 1995 (+ J. Wieling, G. Hendriks, W.J. Tamminga, J. Hempenius and C.K. Mensink).
A Rational Experimental Design for Bioanalytical Methods Validation.
- 124A. Twenty-second Annual Meeting of the Controlled Release Society, Seattle, USA, August 1995 (+ A.A. Dogterom, N.R. Hefting, D. Kanner, B. Jesussek and E. Ezra).
Jet injected growth hormone: in vitro and in vivo comparison with conventional injection.
- 124B. Fourth International ISSX Meeting, Seattle USA, August 1995 (+ E.J. van Hoogdalem, P. Dogterom, H. Kamimura and S. Higuchi).
Pharmacokinetics of intravenously and orally delivered tamsulosin, an α_1 -adrenoreceptorantagonist, in man; interspecies scaling versus preclinical data.

125. Annual meeting of the European Respiratory Society, Barcelona, Spain, September 1995 (+ P. Dogterom, B. Oosterhuis and J.T. Ebels).
Inhaled fluticasone propionate induces greater cortisol suppression compared to budesonide. A dose response study using pressurized metered dose inhalers (PMDI's).
126. First Congress of the European Association for Clinical Pharmacology and Therapeutics, Paris, France, September 1995 (+ M.J. Möbius, A. Gerebtzoff, A. Racine-Poon and C.H. Gleiter).
CGP 36 742, an orally active gaba_B antagonist: gender-related pharmacokinetics in healthy elderly volunteers.
127. First Congress of the European Association for Clinical Pharmacology and Therapeutics, Paris, France, September 1995 (+ H.W. Visscher, J.J. van Lier, J. Wemer, B. Stieren and H. Müller-Pelzer).
Tolerability and pharmacokinetics of dexverapamil after intravenous administration of 250 to 625 mg over 6 hours.
128. First Congress of the European Association for Clinical Pharmacology and Therapeutics, Paris, France, September 1995 (+ E.W.J. Groen, H.R. Schwietert, S.P. van Marle, F.A.E. Sollie, J. Wemer, K. Francis and A. Metcalfe).
Multiple dose administration of recombinant human parathyroid hormone (rhPTH (1-84)) in healthy postmenopausal volunteers.
- 128A. Twenty-first International Epilepsy Congress, Sydney, Australia, September 1995 (+ L. Gustavson, J.A. Jansen, K. Sommerville, K. Wesnes, A. Cohen, G.F. Carlson, R. Marshall, S. Snel, J. Dirach and H. Kastberg).
Tiagabine: evaluation of the risk of interaction with theophylline, warfarin, digoxin, cimetidine, oral contraceptives, triazolam or ethanol.
129. Tenth Annual Meeting and exposition 'Accelerating Drug Discovery and Development' of the American Association of Pharmaceutical Scientists, Miami, USA, November 1995 (+ E.W.J. Groen, H.R. Schwietert, S.P. van Marle, F.A.E. Sollie, J. Wemer, K. Francis and A. Metcalfe).
An evaluation of single dose administration of recombinant human parathyroid hormone (rhPTH 1-84) in healthy post-menopausal female volunteers.

1996

130. Spring meeting of the German Association for Pharmacology and Toxicology, Mainz, Germany, March 1996 (+ C.A.P.F. Su, J.J. van Lier, H.R. Schwietert, J. Stangier and P.J.G. Cornelissen).
Influence of Telmisartan, a non-peptide angiotensin II (A II) receptor antagonist, on steady state pharmacodynamics and pharmacokinetics of warfarin in healthy subjects.
- 130A. Meeting Dutch Asthma Foundation (Nederlands Astma Fonds), Assen, The Netherlands, March 1996 (+ F.I. Jonkman-Broekema).
Biorhythm and Asthma.

131. Sixth European Congress of Biopharmaceutics and Pharmacokinetics, Athens, Greece, April 1996 (+ P. Dogterom, J.J. van Lier, J. Wemer, S. Sabo and P. Glue).
Comparative bioavailability study on interferon alpha-2b administered subcutaneously: lyophilized powder versus a human serum albumin-free sterile solution.
132. Sixth European Congress of Biopharmaceutics and Pharmacokinetics, Athens, Greece, April 1996 (+ C.P.H.M. Spiertz, I.J. Terpstra, L.E. Pope, J.F. Marcelletti, P.N.M. van Heiningen, W.J. Tamminga and E.J. van Hoogdalem).
Pharmacokinetics and metabolism of the antiviral agent n-docosanol after single oral and topical dosing in man.
133. The Fourth Aromatase Conference, Lake Tahoe, USA, June 1996, (+ I.J. Terpstra, P. Dogterom, E.W.J. Groen and J.H.G. Jonkman).
Single increasing dose study with YM511 in healthy pre-menopausal women.
134. Eleventh international conference on aids, Vancouver, Canada, July 1996 (+ P. Pitisuttithum, S. Migasena, P. Suntharasamai, R. Sutthan, P. Perathamond, C. Wasi, U. Schikan, P.A.M. Peeters and A.J. Tobia).
Hypericin: safety and antiretroviral activity in thai HIV positive volunteers.
135. Sixth World Conference on Clinical Pharmacology and Therapeutics, Buenos Aires, Brasil, August 1996 (+ P.A.M. Peeters, H.J.M.J. Crijns, W.J. Tamminga, F.A.E. Sollie, G. Kieffer, J. Necciari and J.P. Dickinson).
Absence of pharmacokinetic interaction between the novel antiplatelet agent, clopidogrel, and digoxin.
136. 18th Congress of the European Society of Cardiology, Birmingham, United Kingdom, August 1996 (+ J.P. Dickinson, P.A.M. Peeters, H.J.M.J. Crijns, W.J. Tamminga, F.A.E. Sollie, G. Kieffer and J. Necciari).
Absence of pharmacokinetic interaction between the novel antiplatelet agent, clopidogrel, and digoxin.
137. Third Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology, Jerusalem, Israel, September 1996 (+ F. Larsen, N.R. Hefting, M. Priskorn, M.S. Mustafa and B. Oosterhuis).
Pharmacokinetics of sertindole in relation to CYP2D6 and CYP2C19 polymorphism and CYP3A4-activity in healthy male volunteers.
138. Second International Congress on Phytomedicine, Munich, Germany, September 1996 (+ K.A. Wesnes, R.A. Faleni, N.R. Hefting, G. Hoogsteen, J.J.G. Houben, J. Leonard, O. Petrini and J.J. van Lier).
The cognitive, subjective and physical effects of Gincosan® in healthy volunteers with neurasthenic complaints.
139. Psychobiology Section, Annual Scientific Meeting, Langdale, Lake District, United Kingdom, September 1996 (+ K.A. Wesnes, R.A. Faleni, N.R. Hefting, G. Hoogsteen, J.J.G. Houben, J. Leonard, O. Petrini and J.J. van Lier).
The cognitive, subjective and physical effects of Gincosan® in healthy volunteers with neurasthenic complaints.

140. Mededelingendag Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Utrecht, The Netherlands, October 1996 (+ H. Groen, J.J. van Lier, F.A.E. Sollie, J. Wemer, J.H.G. Jonkman, M.-L. Huang, R. Woestenborghs and A. van Peer).
The pharmacokinetics of vorozole in young healthy males, healthy post-menopausal females aged up to 65 and healthy elderly females aged 70 or over.
141. Fourteenth international congress for tropical medicine and malaria, Nagasaki, Japan, November 1996 (+ B. Oosterhuis, P.A.M. Peeters, F.A.E. Sollie, Ch.B. Lugt, J.O. Peggins, D.E. Kyle and S. Looareesuwan).
Antimalarial pharmacodynamics of β -arteether (Artecef® adult) in relation to its pharmacokinetics in patients and healthy volunteers.
142. Fourteenth international congress for tropical medicine and malaria, Nagasaki, Japan, November 1996 (+ P.A.M. Peeters, J.J. van Lier, Ch.B. Lugt, J.H.G. Jonkman, J.O. Peggins and B. Oosterhuis).
Multiple dose phase I study on the safety, tolerability and pharmacokinetics of β -arteether (Artecef® adult) after intramuscular injection in healthy volunteers.
143. Fourteenth international congress for tropical medicine and malaria, Nagasaki, Japan, November 1996 (+ C.M. Osborne, P.E. Thuma, G.J. Bhat, V.R. Gordeuk, G.F. Mabeza, G. Biemba, P.A.M. Peeters and Ch.B. Lugt).
Efficacy and safety of β -arteether (Artecef® paediatric) in Zambian children with cerebral malaria.
144. Fourteenth international congress for tropical medicine and malaria, Nagasaki, Japan, November 1996 (+ S. Looareesuwan, P. Wilairatena, S. Vanajanonta, B. Oosterhuis, P.A.M. Peeters, Ch.B. Lugt, P. Teja-isavadharm and D.E. Kyle).
Clinical experiences on β -arteether (Artecef® adult) in the management of falciparum malaria in Thailand.
145. Fourteenth international congress for tropical medicine and malaria, Nagasaki, Japan, November 1996 (+ U. Rickenbacher, H. Becker, J. Dubach-Powell and Ch.B. Lugt).
Effects of β -arteether (Artecef® adult) on the spermatogenesis of male rats.

1997

146. IOCD/CYTED International Joint Symposium: Chemistry, Biological and Pharmacological Properties of Medicinal Plants in the Americas, Panama, U.S.A., February 1997 (+ K.A. Wesnes, R.A. Faleni, N. Hefting, G. Hoogsteen, J. Houben, J. Leonard, O. Petrini and J.J. van Lier).
The cognitive, subjective and physical effects of gincosan in healthy volunteers with neurasthenic complaints.
147. Symposium van de Federatie Industrie Artsen, Berghem/Oss, The Netherlands, March 1997 (J.H.G. Jonkman).
Quality Management in Clinical Research.

148. 31st Annual Scientific Meeting of European Society for Clinical Investigation, Kiel, Germany, March 1997 (+ K.A. Wesnes, R.A. Faleni, N. Hefting, G. Hoogsteen, J. Houben, J. Leonard, O. Petrini and J.J. van Lier).
The cognitive, subjective and physical effects of gincosan in healthy volunteers with neurasthenic complaints, in workshop entitled: Assessing the pharmacodynamics and pharmacokinetics of neuropharmacological agents.
149. Mededelingendag van de Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Leiden, The Netherlands, April 1997 (+ H. Groen, J.J. van Lier, F.A.E. Sollie, J. Wemer, M.-L. Huang, R. Woestenborghs and A. van Peer).
The pharmacokinetic dose-proportionality of 1, 2.5 and 5 mg vorozole in healthy postmenopausal females.
- 149A. Mededelingendag van de Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Leiden, The Netherlands, April 1997 (+ B. Oosterhuis, P.A.M. Peeters, F.A.E. Sollie, Ch.B. Lugt, J.O. Peggins, D.E. Kyle, J.H.G. Jonkman and S. Looareesuwan).
 β -arteether antimalarial pharmacodynamics in relation to its pharmacokinetics in patients and healthy volunteers.
150. Eighth International Symposium on Pharmaceutical and Biomedical Analysis, Kissimmee, USA, May 1997 (+ N.C. van de Merbel, A.P. Tinke, W.D. van Dongen, B. Oosterhuis, Ph. Ladure and C. Puozzo).
A validated method for the determination of idazoxan in human plasma by liquid chromatography with tandem mass-spectrometric detection.
151. 37th Annual NCDEU Meeting, Boca Raton, (Fl.), U.S.A., May 1997 (+ K.A. Wesnes, R.A. Faleni, N. Hefting, G. Hoogsteen, J. Houben, J. Leonard, O. Petrini and J.J. van Lier).
The cognitive, subjective and physical effects of a combination of Panax Ginseng and Ginkgo Biloba in healthy volunteers with neurasthenic complaints.
152. 45th ASMS Conference on Mass Spectrometry, Palm Springs, (Fl.), U.S.A., June 1997 (+ W.D. van Dongen, M. Honing, A.P. Tinke, N.C. van de Merbel, B. Oosterhuis and Ch.B. Lugt).
An ionspray LC-MS/MS method for the quantitative determination of dihydroartemisinin in human plasma.
153. GIDS Spring Meeting, Groningen, The Netherlands, June 1997 (+ W.J. Tamminga, J. Wemer, B. Oosterhuis, B. Wilffert, L.F.M.H. de Ley and R.A. de Zeeuw).
Phenotyping and genotyping techniques used in clinical pharmacology studies.
154. 21st International Symposium on High Performance Liquid Phase Separations and Related Techniques, June 1997, Birmingham, England (+ J.P.G. Brakenhoff, N.C. van de Merbel, G. Wilkens and B. Oosterhuis).
LC-phases improve, but not all assays do: metformin bioanalysis revisited.
155. 22nd International Epilepsy Congress, Dublin, Ireland, June/July 1997 (+ M.S. Thomsen, L. Groes, H.R. Schwietert, J. Wemer, T. Andreasen, J.M. Gillin, S. van der Poel, H. Agero and J.A. Jansen).
Tiagabine: investigation of possible interaction with erythromycin during multiple dosing in healthy volunteers.

156. 16th International Diabetes Congress, Helsinki, Finland, July 1997 (+ M.M.R. Young, L. Squassante, J. Wemer, S.P. van Marle and P. Dogterom).
Troglitazone has no effect on the Red Cell Mass or other erythropoietic parameters.
157. 2nd Congress of the European Association for Clinical Pharmacology and Therapeutics, Berlin, Germany, September 1997 (+ H. Groen, J.J. van Lier, F.A.E. Sollie, J. Wemer, M.-L. Huang, R. Woestenborghs and A. van Peer).
Pharmacokinetic characterization of vorozole in young healthy males, healthy postmenopausal females aged up to 65 and healthy elderly females aged 70 or over.
158. 2nd Congress of the European Association for Clinical Pharmacology and Therapeutics, Berlin, Germany, September 1997 (+ J. Wemer, H. Groen, J.J. van Lier, F.A.E. Sollie, M.-L. Huang, R. Woestenborghs and A. van Peer).
On the dose-proportionality of 1, 2.5 and 5 mg vorozole in healthy postmenopausal females.
159. 2nd Congress of the European Association for Clinical Pharmacology and Therapeutics, Berlin, Germany, September 1997 (+ H.R. Schwieter, J. Wemer, M.S. Thomsen and V. Hatorp).
Co-administration of repaglinide does not affect digoxin pharmacokinetics.
160. 2nd Congress of the European Association for Clinical Pharmacology and Therapeutics, Berlin, Germany, September 1997 (+ H.R. Schwieter, J. Wemer, V. Hatorp and M.S. Thomsen).
No change in repaglinide pharmacokinetics with cimetidine co-administration.
161. European Respiratory Society, Annual Congress, Berlin, Germany, September 1997 (+ C. Falcoz, C. Lawlor, N.G. Borgstein, F.W.M. Smeets, J. Wemer and F. House).
Effects of CYP450 3A inhibition by ketoconazole on systemic activity of inhaled fluticasone propionate and budesonide.
162. British Psychological Society Psychobiology Section Annual Scientific Meeting, Lake District, United Kingdom, September 1997 (+ K.A. Wesnes, R.A. Faleni, N. Hefting, G. Hoogsteen, J. Houben, J. Leonard, O. Petrini and J.J. van Lier).
The cognitive, subjective and physical effects of gincosan in healthy volunteers with neurasthenic complaints.
163. Advances in Pharmacology and Therapeutics with Angiotensin II Receptor Antagonists, Satellite symposium of the First International Symposium on Angiotensin II Antagonism, London, England, September/October 1997 (+ A.M. Högemann).
Drug interaction and candesartan cilexetil.
164. Advances in Pharmacology and Therapeutics with Angiotensin II Receptor Antagonists, Satellite symposium of the First International Symposium on Angiotensin II Antagonism, London, England, September/October 1997 (+ J. Stangier, J. Schmid, D. Türck).
Pharmacokinetics and metabolism of [¹⁴C] radio-labelled telmisartan, a potent angiotensin II antagonist, in healthy male subjects.
165. Mededelingendag van de Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Utrecht, The Netherlands, October 1997 (+ W.J. Tamminga, J. Wemer, B. Oosterhuis, B. Wilffert, L.F.M.H. de Ley, R.A. de Zeeuw).
The application of phenotyping and genotyping techniques in clinical pharmacology studies.

166. Vereniging Klinisch Chemici Noord, Groningen, The Netherlands, October 1997
(J.H.G. Jonkman)
Good Laboratory Practice (GLP) during new drug development.
167. IVth European Congress on Menopause, Vienna, Austria, October 1997
(D.Geyer, J.J. van Lier, P. Blain, M.G.F. Gerrits, J. Wemer, J.H.G. Jonkman, A. Renoux).
The size of a transdermal estrogen patch - Fem77 - corresponds to hormone plasma levels.
168. Najaarsbijeenkomst van de Nederlandse Vereniging voor Massaspectrometrie, 's-Hertogenbosch, The Netherlands, November 1997
(J. Wieling).
Good Laboratory Practice: waarom en hoe?
169. Nederlandse Vereniging voor Farmaceutische Wetenschappen, NVFW Toogdag, Geneesmiddelenonderzoek in Nederland, Leiden, The Netherlands, November 1997
(+ W.J. Tamminga, B. Oosterhuis, J. Wemer, J. Wieling, B. Wilffert, E.P. Sakiman, R.A. de Zeeuw, L.F.M.H. de Ley).
Mephenytoin as a marker for CYP2C19 enzyme activity.
170. American Heart Association, International Council on the Role of Aldosterone in Cardiovascular Disease, Orlando, Florida, U.S.A., November 1997
(A.A. van Vliet).
Excretion balance and pharmacokinetics after single dose oral intake of ¹⁴C-SC-66110 by healthy volunteers.
171. Meeting British Society for Mass Spectrometry, Cambridge, United Kingdom, December 1997
(R.J.J.M. Steenvoorden, M. Honing, J. Wieling, B. Oosterhuis).
A highly sensitive and high-throughput assay method for the determination of morphine and its two glucuronide metabolites in human plasma using HPLC-MS/MS.

1998

172. Nederlandse Vereniging Medisch-Ethische Toetsingscommissies, February 1998
(W. Russchen).
Standard Operating Procedures (SOP's).
173. Animal Experiments in Medical Research, University of Groningen, Central Animal Laboratory, Groningen, The Netherlands, March 1998
(J.H.G. Jonkman).
Good Laboratory Practice in the animal laboratory.
174. 39th Spring Meeting organized by Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, Mainz, Germany, March 1998
(B. Wilffert, W.J. Tamminga, J. Wemer, B. Oosterhuis, J. Wieling, J.H.G. Jonkman, L.F.M.H. de Ley, R.A. de Zeeuw).
Distribution of CYP2D6 and CYP2C19 phenotypes in dutch male and female volunteers in clinical pharmacology studies.
175. NFIA Life Sciences Seminar, Palo Alto, USA, April 1998
(J.H.G. Jonkman).
Outsourcing of drug development in Europe.

176. Training Course on Total Quality Assurance and Quality Management, The development of new medicines in the pharmaceutical industry: from idea to registration dossier, Delft, The Netherlands, April 1998
(J.H.G. Jonkman).
Clinical pharmacology, with special emphasis on Phase I clinical studies.
177. Training Course on Total Quality Assurance and Quality Management, The development of new medicines in the pharmaceutical industry: from idea to registration dossier, Delft, The Netherlands, April 1998
(J.H.G. Jonkman).
Quality Management during the clinical drug development process. All aspects of quality management (including Good Clinical Practice) during Phase II and III studies.
178. Mededelingendag Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Amsterdam, The Netherlands, April 1998
(P.A.M. Peeters, J. Beukema, B. Oosterhuis, F.W.M. Smeets, R.S. Moyou, F. Thietche, C.M. Osborne, P.E. Thuma, G.J. Bhat, G. Biemba, G.M. Shakankale, J.H.G. Jonkman, Ch.B. Lugt).
 β -arteether (Artecef® paediatric): efficacy and safety in African children with cerebral malaria.
179. Spring Meeting Groningen Institute for Drug Studies (GIDS), Groningen, The Netherlands, May 1998
(J. Wemer, W. Tamminga, B. Oosterhuis, B. Wilffert, J. Wieling, J.H.G. Jonkman, R.A. de Zeeuw, L.F.M.H. de Leij).
Pharmacogenetic aspects of drug metabolism in drug development.
180. Spring Meeting Groningen Institute for Drug Studies (GIDS), Groningen, The Netherlands, May 1998
(W.J. Tamminga, B. Oosterhuis, J. Wemer, J. Wieling, B. Wilffert, H. Poelman, R.A. de Zeeuw, L.F.M.H. de Leij, J.H.G. Jonkman).
CYP2C19 phenotyping and genotyping in Dutch volunteers in clinical pharmacology studies.
181. Drug Analysis '98 Symposium, Brussels, Belgium, May 1998
(J. Wieling, B. Oosterhuis, J.H.G. Jonkman).
Bioanalytical support in first-dosing-in man studies.
182. 22nd International Symposium on High Performance Liquid Phase Separations and Related Techniques, St. Louis, USA, May 1998
(N.C. van de Merbel, J.H. van Veen, G. Wilkens, J.H.G. Jonkman and G.R. Loewen).
Liquid chromatographic determination of Targretin® in human plasma: the importance of understanding sample preparation.
183. European Symposium on the Prediction of Drug Metabolism in Man: Progress and Problems, Liège, Belgium, May 1998
(B. Oosterhuis, W.J. Tamminga, J. Wemer, J. Wieling, B. Wilffert, E.P. Sakiman, R.A. de Zeeuw, L.F.M.H. de Ley, J.H.G. Jonkman).
Mephenytoin as a marker for CYP2C19 activity: influence of analytical factors on the outcome of phenotyping.

184. 46th ASMS Conference on Mass Spectrometry and Allied Topics Orlando, Florida, USA May/June 1998
(W.D. van Dongen, F.M. Lagerwerf, R.J.J.M. Steenvoorden, J. Wieling, J.H.G. Jonkman).
Exploring the boundaries of quantitative HPLC-MS/MS.
185. 58th Scientific Sessions, American Diabetes Association, Chicago, USA, June 1998
(P. Dogterom, J.H.G. Jonkman, N.G. Borgstein, S. Vallance, R. Patwardhan).
Rosiglitazone (BRL 49653): No effect on erythropoiesis or premature red cell destruction.
186. Clinical Dermatology 2000, Singapore, Malaysia, June 1998
(P. Burtin, M-E. Ebelin, R. Laplanche, J.J. Thébault, J. Wemer).
Low systemic exposure and good tolerability of SDZ ASM 981 after short-term topical application in healthy volunteers and atopic patients.
187. GUIDE Course 'Design, conduction and evaluation of clinical trial', University Hospital, Groningen, The Netherlands, June 1998
(B. Oosterhuis and J.H.G. Jonkman).
Metoprolol in Phase I.
188. International Congress on Automation and Robotics/MipTec98, Basel, Switzerland, June 1998
(J.J.H. Klijn, J. Hempenius and J.H.G. Jonkman).
Comparison between positive and negative pressure liquid handling robots for solid phase extraction using 3M™ Empore™ 96 well extraction disk plates.
189. 12th International Symposium on Microsomes and Drug Oxidations, Montpellier, France, July 1998
(W.J. Tamminga, B. Oosterhuis, J. Wemer, J. Wieling, B. Wilffert, H. Poelman, R.A. de Zeeuw, L.F.M.H. de Leij, J.H.G. Jonkman).
CYP2C19 activity in a large sample of the dutch population.
190. Symposium 'Verleiding en Misleiding, de waarheid in de wetenschap', Veldhoven, The Netherlands, September 1998
(J.H.G. Jonkman).
De Vermijding.
191. Mededelingendag Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Utrecht, The Netherlands, October 1998
(J.J. van Lier, P.A.M. Peeters, A.A. van Vliet, J. Wemer, N. van de Merbel, B. Oosterhuis, J. Wieling, K. Klessing, A. Biber, J.H.G. Jonkman).
Excretion balance, pharmacokinetic and metabolism study after single oral doses of [¹⁴C]-labelled losigamone and both enantiomers in healthy male volunteers.
192. Mededelingendag Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie, Utrecht, The Netherlands, October 1998
(W.J. Tamminga, J. Wemer, B. Oosterhuis, J. Wieling, B. Wilffert, R.A. de Zeeuw, L.F.M.H. de Leij, J.H.G. Jonkman).
Evidence for gender differences on CYP2C19 activity in Dutch healthy volunteers in clinical pharmacology studies.

193. International Symposium on Laboratory Automation and Robotics, Boston, USA, October 1998 (J. Wieling, J. Hempenius, R.J.J.M. Steenvoorden, J.H.G. Jonkman).
A comparison of pressure and vacuum based automated 96-well SPE systems for the LC-MS-MS bioanalysis of haloperidol in plasma.
194. Minisymposium 'Where can clinical pharmacology contribute?', Amsterdam, The Netherlands, October 1998 (A.A. van Vliet).
Where can clinical pharmacology contribute in industry and CRO.
195. First POA Symposium 'Voeding, Suppletie & Geneesmiddelen, Werking en Wisselwerking', Utrecht, The Netherlands, November 1998 (B. Oosterhuis).
Interacties Geneesmiddelen en Voeding.
196. DIA Workshop 'Informed Consent: Value, Responsibilities, Procedures – Who is it Protecting?', Brussels, Belgium, November 1998 (J.H.G. Jonkman).
Informed Consent in Healthy Volunteers.
197. Nederlandse Vereniging voor Farmaceutische Wetenschappen, NVFW Toogdag, Utrecht, The Netherlands, November 1998 (J.H.G. Jonkman).
Modern Kwaliteitsmanagement in Biomedisch en Farmaceutisch Onderzoek.
198. Fifth EUFEPS Conference 'Optimising Drug Development: Fast tracking into Human', Wiesbaden, Germany, December 1998 (B. Wilffert, W.J. Tamminga, B. Oosterhuis, J. Wemer, J. Wieling, R.A. de Zeeuw, L.F.M.H. de Leij, J.H.G. Jonkman).
On the role of genotyping and phenotyping for characterization of CYP2C19 activity as a tool for optimization of clinical pharmacology studies.
199. 1998 Wubbo Ockels Award of the City of Groningen, Groningen, December 1998 (J.H.G. Jonkman)
Pharmacogenetic aspects of drug development and pharmacotherapy ('on genotyping and phenotyping').

1999

200. 1999 EFGCP Annual Conference: Humanising GCP: Values, Safety, and Public Health, Brussels, Belgium, January 1999 (J.H.G. Jonkman)
Promoting Standards in Pharmaceutical Research for Public Health.
201. Nederlandse Vereniging van Medisch-Ethische Toetsingcommissies, Utrecht, The Netherlands, February 1999 (J.H.G. Jonkman).
Fraude bij medisch-wetenschappelijk onderzoek.

202. Cursus Stichting Registratie Industrie Apothekers 'Industriële Research & Development', Oss, The Netherlands, March 1999
(B. Oosterhuis).
Introduction on new drug development.
203. 1st International Symposium on Separations in the Biosciences (SBS'99),
Amsterdam, The Netherlands, March 1999
(J. Wieling and J.H.G. Jonkman).
High-throughput bioanalysis of drugs using automated solid-phase extraction.

2000

204. Training Course on Quality Assurance and Total Quality Management,
Delft, The Netherlands, April 2000
(J.H.G. Jonkman).
Survey of Quality Systems

2001

205. Training Course on Quality Assurance and Total Quality Management
Delft, The Netherlands, January 2001
(J.H.G. Jonkman).
Survey of Quality Systems
206. Animal Experiments in Medical Research
University of Groningen
Course Research in Animals
Groningen, The Netherlands, March 2001
(J.H.G. Jonkman).
Good Laboratory Practice in the Animal Laboratory
207. Mededelingendag Nederlandse Vereniging voor Klinische Farmacologie en Biofarmacie
Lunteren, The Netherlands, April 2001
(W.J. Tamminga, J. Wemer, B. Oosterhuis, A. de Boer, S. Vranckx, B.F.H. Drenth, R.A. de Zeeuw, L.F.M.H. de Leij, J.H.G. Jonkman)
The influence of polymorphic drug metabolism (CYP2D6) on the pharmacotherapy of hospitalised psychiatric patients
208. 5th Congress of the European Association for Clinical Pharmacology and Therapeutics, Odense,
Denmark, September 2001
(+W.J. Tamminga, J. Wemer, B. Oosterhuis, A. de Boer, S. Vranckx, B.F.H. Drenth, R.A. de Zeeuw, L.F.M.H. de Leij)
The pharmacotherapy of hospitalised psychiatric patients related to CYP2D6 genotypes.
209. Mededelingendag Nederlands Vereniging voor Klinische Farmacologie en Biofarmacie
Lunteren, The Netherlands, October 2001
(W.J. Tamminga, J. Wemer, B. Oosterhuis, R.A. de Zeeuw, L.F.M.H. de Leij, J.H.G. Jonkman)
The prevalence of CYP2C19 genotypes in a population of healthy Dutch volunteers and apparent gender differences in phenotypes.

2003

210. FABIAN Symposium,
Groningen, The Netherlands, November 2003
(J.H.G. Jonkman)
Quality Management in bioscience

2005

211. Oriëntatie Geneesmiddelen Onderzoek
Pharmaceutical Analysis Group
University of Groningen,
Groningen, The Netherlands, January 2005
(J.H.G. Jonkman)
Drug Research and Development and Good Laboratory Practice (GLP)
212. Rotary Club Assen
Assen, The Netherlands, September 2005
(J.H.G. Jonkman)
Geneesmiddelen in Nederland te duur?

2006

213. Applied Clinical Trials European Summit 2006
Amsterdam, The Netherlands, September 2006
(J.H.G. Jonkman)
The changing nature of ethical review.

2007

214. Annual Conference ACRON,
Utrecht, The Netherlands, March 2007
(J.H.G. Jonkman)
Certification of Clinical Research Staff
215. Rotary Club Assen
Assen, The Netherlands, May 2007
(J.H.G. Jonkman)
Geneesmiddelengebruik door Senioren
216. Conference of Association of Clinical Research Staff (ACRP)
Amsterdam, The Netherlands, June 2007
(J.H.G. Jonkman)
Certification of (Clinical) Research Staff

217. Training Course Ph.D. Programme, University of Groningen
Groningen, The Netherlands, June 2007
(J.H.G. Jonkman)
Medical Ethical Review committees in the Netherlands

2008

218. Glaxo Smith Kline Clinical Research Department
Zeist, The Netherlands, February 2008
(J.H.G. Jonkman)
Quality Management in Clinical Research
- Rotary Club Assen
Assen, The Netherlands, August 2008
(J.H.G. Jonkman)
Geneesmiddelen en Kinderen

2009

219. Summerschool University of Groningen/University Medical Centre Groningen
Choosing your career in the life sciences: Science and an Entrepreneurship in Groningen
Bakkeveen, The Netherlands, August 2009
(J.H.G. Jonkman)
Can a scientist be an entrepreneur?
220. Symposium 25 jaar Stichting BEBO
Stichting Beoordeling Ethiek Biomedisch Onderzoek "Medisch-ethisch toetsen in Nederland:
Quo Vadis"
Assen, The Netherlands, October 2009
(J.H.G. Jonkman)
Toetsen in de toekomst: wat speelt er in Europa?
221. Symposium ter gelegenheid van het 10-jarig bestaan van Pentheccilia
Rotterdam, The Netherlands, June 2010
(J.H.G. Jonkman)
Kwaliteit heeft een prijs.